id	sid	tid	token	lemma	pos
ajcp-747	1	1	pa	pa	PROPN
ajcp-747	1	2	ge	ge	PROPN
ajcp-747	1	3	1	1	NUM
ajcp-747	1	4	pa	pa	PROPN
ajcp-747	1	5	ge	ge	PROPN
ajcp-747	1	6	1	1	NUM
ajcp-747	1	7	american	american	PROPN
ajcp-747	1	8	journal	journal	PROPN
ajcp-747	1	9	of	of	ADP
ajcp-747	1	10	chemistry	chemistry	NOUN
ajcp-747	1	11	and	and	CCONJ
ajcp-747	1	12	pharmacy	pharmacy	NOUN
ajcp-747	1	13	(	(	PUNCT
ajcp-747	1	14	ajcp	ajcp	NOUN
ajcp-747	1	15	)	)	PUNCT
ajcp-747	1	16	empagliflozin	empagliflozin	PROPN
ajcp-747	1	17	-	-	PUNCT
ajcp-747	1	18	induced	induce	VERB
ajcp-747	1	19	acute	acute	ADJ
ajcp-747	1	20	pancreatitis	pancreatitis	PROPN
ajcp-747	1	21	and	and	CCONJ
ajcp-747	1	22	euglycemic	euglycemic	ADJ
ajcp-747	1	23	diabetic	diabetic	ADJ
ajcp-747	1	24	ketoacidosis	ketoacidosis	NOUN
ajcp-747	1	25	in	in	ADP
ajcp-747	1	26	type	type	NOUN
ajcp-747	1	27	2	2	NUM
ajcp-747	1	28	diabetes	diabetes	NOUN
ajcp-747	1	29	mellitus	mellitus	NOUN
ajcp-747	1	30	yasser	yasser	PROPN
ajcp-747	1	31	sadawey1	sadawey1	PROPN
ajcp-747	1	32	*	*	PROPN
ajcp-747	1	33	,	,	PUNCT
ajcp-747	1	34	hesham	hesham	PROPN
ajcp-747	1	35	metwally2	metwally2	PROPN
ajcp-747	1	36	volume	volume	NOUN
ajcp-747	1	37	1	1	NUM
ajcp-747	1	38	issue	issue	NOUN
ajcp-747	1	39	2	2	NUM
ajcp-747	1	40	,	,	PUNCT
ajcp-747	1	41	year	year	NOUN
ajcp-747	1	42	2022	2022	NUM
ajcp-747	1	43	issn	issn	X
ajcp-747	1	44	:	:	PUNCT
ajcp-747	1	45	2834	2834	NUM
ajcp-747	1	46	-	-	SYM
ajcp-747	1	47	0116	0116	NUM
ajcp-747	1	48	(	(	PUNCT
ajcp-747	1	49	online	online	ADJ
ajcp-747	1	50	)	)	PUNCT
ajcp-747	1	51	doi	doi	NOUN
ajcp-747	1	52	:	:	PUNCT
ajcp-747	1	53	https://doi.org/10.54536/ajcp.v1i2.747	https://doi.org/10.54536/ajcp.v1i2.747	VERB
ajcp-747	1	54	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-747	1	55	article	article	NOUN
ajcp-747	1	56	information	information	NOUN
ajcp-747	1	57	abstract	abstract	ADV
ajcp-747	1	58	received	receive	VERB
ajcp-747	1	59	:	:	PUNCT
ajcp-747	1	60	october	october	PROPN
ajcp-747	1	61	11	11	NUM
ajcp-747	1	62	,	,	PUNCT
ajcp-747	1	63	2022	2022	NUM
ajcp-747	1	64	accepted	accept	VERB
ajcp-747	1	65	:	:	PUNCT
ajcp-747	1	66	october	october	PROPN
ajcp-747	1	67	19	19	NUM
ajcp-747	1	68	,	,	PUNCT
ajcp-747	1	69	2022	2022	NUM
ajcp-747	1	70	published	publish	VERB
ajcp-747	1	71	:	:	PUNCT
ajcp-747	1	72	october	october	PROPN
ajcp-747	1	73	23	23	NUM
ajcp-747	1	74	,	,	PUNCT
ajcp-747	1	75	2022	2022	NUM
ajcp-747	1	76	acute	acute	PROPN
ajcp-747	1	77	pancreatitis	pancreatitis	PROPN
ajcp-747	1	78	and	and	CCONJ
ajcp-747	1	79	euglycemic	euglycemic	PROPN
ajcp-747	1	80	dka	dka	PROPN
ajcp-747	1	81	,	,	PUNCT
ajcp-747	1	82	edka	edka	NOUN
ajcp-747	1	83	,	,	PUNCT
ajcp-747	1	84	are	be	AUX
ajcp-747	1	85	uncommon	uncommon	ADJ
ajcp-747	1	86	but	but	CCONJ
ajcp-747	1	87	potentially	potentially	ADV
ajcp-747	1	88	fatal	fatal	ADJ
ajcp-747	1	89	complications	complication	NOUN
ajcp-747	1	90	in	in	ADP
ajcp-747	1	91	diabetic	diabetic	ADJ
ajcp-747	1	92	patients	patient	NOUN
ajcp-747	1	93	on	on	ADP
ajcp-747	1	94	sodium	sodium	NOUN
ajcp-747	1	95	-	-	PUNCT
ajcp-747	1	96	glucose	glucose	NOUN
ajcp-747	1	97	cotransporter	cotransporter	NOUN
ajcp-747	1	98	2	2	NUM
ajcp-747	1	99	inhibitors	inhibitor	NOUN
ajcp-747	1	100	(	(	PUNCT
ajcp-747	1	101	sglt2	sglt2	NOUN
ajcp-747	1	102	)	)	PUNCT
ajcp-747	1	103	.	.	PUNCT
ajcp-747	2	1	this	this	DET
ajcp-747	2	2	case	case	NOUN
ajcp-747	2	3	report	report	NOUN
ajcp-747	2	4	presents	present	VERB
ajcp-747	2	5	the	the	DET
ajcp-747	2	6	exceptional	exceptional	ADJ
ajcp-747	2	7	occurrence	occurrence	NOUN
ajcp-747	2	8	of	of	ADP
ajcp-747	2	9	a	a	DET
ajcp-747	2	10	49	49	NUM
ajcp-747	2	11	-	-	PUNCT
ajcp-747	2	12	year	year	NOUN
ajcp-747	2	13	-	-	PUNCT
ajcp-747	2	14	old	old	ADJ
ajcp-747	2	15	;	;	PUNCT
ajcp-747	2	16	male	male	ADJ
ajcp-747	2	17	patient	patient	NOUN
ajcp-747	2	18	diagnosed	diagnose	VERB
ajcp-747	2	19	with	with	ADP
ajcp-747	2	20	empagliflozin	empagliflozin	NOUN
ajcp-747	2	21	-	-	PUNCT
ajcp-747	2	22	induced	induce	VERB
ajcp-747	2	23	edka	edka	NOUN
ajcp-747	2	24	coupled	couple	VERB
ajcp-747	2	25	with	with	ADP
ajcp-747	2	26	t2	t2	PROPN
ajcp-747	2	27	dm	dm	PROPN
ajcp-747	2	28	as	as	ADP
ajcp-747	2	29	a	a	DET
ajcp-747	2	30	precursor	precursor	NOUN
ajcp-747	2	31	to	to	ADP
ajcp-747	2	32	acute	acute	NOUN
ajcp-747	2	33	pancreatitis	pancreatitis	PROPN
ajcp-747	2	34	.	.	PUNCT
ajcp-747	3	1	euglycemic	euglycemic	PROPN
ajcp-747	3	2	dka	dka	PROPN
ajcp-747	3	3	may	may	AUX
ajcp-747	3	4	be	be	AUX
ajcp-747	3	5	produced	produce	VERB
ajcp-747	3	6	after	after	ADP
ajcp-747	3	7	administering	administer	VERB
ajcp-747	3	8	just	just	ADV
ajcp-747	3	9	one	one	NUM
ajcp-747	3	10	dose	dose	NOUN
ajcp-747	3	11	of	of	ADP
ajcp-747	3	12	sglt2	sglt2	PROPN
ajcp-747	3	13	.	.	PUNCT
ajcp-747	4	1	on	on	ADP
ajcp-747	4	2	discharge	discharge	NOUN
ajcp-747	4	3	,	,	PUNCT
ajcp-747	4	4	empagliflozin	empagliflozin	PROPN
ajcp-747	4	5	was	be	AUX
ajcp-747	4	6	managed	manage	VERB
ajcp-747	4	7	to	to	PART
ajcp-747	4	8	stop	stop	VERB
ajcp-747	4	9	.	.	PUNCT
ajcp-747	5	1	since	since	SCONJ
ajcp-747	5	2	the	the	DET
ajcp-747	5	3	initial	initial	ADJ
ajcp-747	5	4	administration	administration	NOUN
ajcp-747	5	5	of	of	ADP
ajcp-747	5	6	sglt2	sglt2	PROPN
ajcp-747	5	7	,	,	PUNCT
ajcp-747	5	8	this	this	DET
ajcp-747	5	9	diagnosis	diagnosis	NOUN
ajcp-747	5	10	should	should	AUX
ajcp-747	5	11	be	be	AUX
ajcp-747	5	12	considered	consider	VERB
ajcp-747	5	13	a	a	DET
ajcp-747	5	14	potential	potential	ADJ
ajcp-747	5	15	consequence	consequence	NOUN
ajcp-747	5	16	.	.	PUNCT
ajcp-747	6	1	appropriate	appropriate	ADJ
ajcp-747	6	2	medical	medical	ADJ
ajcp-747	6	3	treatment	treatment	NOUN
ajcp-747	6	4	is	be	AUX
ajcp-747	6	5	made	make	VERB
ajcp-747	6	6	possible	possible	ADJ
ajcp-747	6	7	by	by	ADP
ajcp-747	6	8	diagnosing	diagnose	VERB
ajcp-747	6	9	and	and	CCONJ
ajcp-747	6	10	treating	treat	VERB
ajcp-747	6	11	this	this	DET
ajcp-747	6	12	life	life	NOUN
ajcp-747	6	13	-	-	PUNCT
ajcp-747	6	14	threatening	threaten	VERB
ajcp-747	6	15	condition	condition	NOUN
ajcp-747	6	16	promptly.keywords	promptly.keywords	ADP
ajcp-747	6	17	diabetic	diabetic	ADJ
ajcp-747	6	18	ketoacidosis	ketoacidosis	NOUN
ajcp-747	6	19	,	,	PUNCT
ajcp-747	6	20	euglycemic	euglycemic	PROPN
ajcp-747	6	21	dka	dka	PROPN
ajcp-747	6	22	,	,	PUNCT
ajcp-747	6	23	sodium	sodium	NOUN
ajcp-747	6	24	-	-	PUNCT
ajcp-747	6	25	glucose	glucose	NOUN
ajcp-747	6	26	cotransporter-2	cotransporter-2	NUM
ajcp-747	6	27	,	,	PUNCT
ajcp-747	6	28	empagliflozin	empagliflozin	PROPN
ajcp-747	6	29	,	,	PUNCT
ajcp-747	6	30	type	type	NOUN
ajcp-747	6	31	2	2	NUM
ajcp-747	6	32	diabetes	diabetes	NOUN
ajcp-747	6	33	mellitus	mellitus	NOUN
ajcp-747	6	34	,	,	PUNCT
ajcp-747	6	35	pancreatitis	pancreatitis	PROPN
ajcp-747	6	36	.	.	PUNCT
ajcp-747	7	1	1	1	NUM
ajcp-747	7	2	department	department	NOUN
ajcp-747	7	3	of	of	ADP
ajcp-747	7	4	medicine	medicine	NOUN
ajcp-747	7	5	,	,	PUNCT
ajcp-747	7	6	mediclinic	mediclinic	ADJ
ajcp-747	7	7	me	i	PRON
ajcp-747	7	8	,	,	PUNCT
ajcp-747	7	9	al	al	PROPN
ajcp-747	7	10	jowhara	jowhara	PROPN
ajcp-747	7	11	hospital	hospital	PROPN
ajcp-747	7	12	,	,	PUNCT
ajcp-747	7	13	al	al	PROPN
ajcp-747	7	14	ain	ain	PROPN
ajcp-747	7	15	,	,	PUNCT
ajcp-747	7	16	uae	uae	PROPN
ajcp-747	7	17	2	2	NUM
ajcp-747	7	18	department	department	NOUN
ajcp-747	7	19	of	of	ADP
ajcp-747	7	20	radiology	radiology	NOUN
ajcp-747	7	21	,	,	PUNCT
ajcp-747	7	22	mediclinic	mediclinic	ADJ
ajcp-747	7	23	me	i	PRON
ajcp-747	7	24	,	,	PUNCT
ajcp-747	7	25	al	al	PROPN
ajcp-747	7	26	jowhara	jowhara	PROPN
ajcp-747	7	27	hospital	hospital	PROPN
ajcp-747	7	28	,	,	PUNCT
ajcp-747	7	29	al	al	PROPN
ajcp-747	7	30	ain	ain	PROPN
ajcp-747	7	31	,	,	PUNCT
ajcp-747	7	32	uae	uae	PROPN
ajcp-747	7	33	*	*	PUNCT
ajcp-747	7	34	corresponding	correspond	VERB
ajcp-747	7	35	author	author	NOUN
ajcp-747	7	36	’s	’s	PART
ajcp-747	7	37	e	e	NOUN
ajcp-747	7	38	-	-	NOUN
ajcp-747	7	39	mail	mail	NOUN
ajcp-747	7	40	:	:	PUNCT
ajcp-747	7	41	dr.yassersadawey@gmail.com	dr.yassersadawey@gmail.com	NOUN
ajcp-747	7	42	introduction	introduction	NOUN
ajcp-747	7	43	the	the	DET
ajcp-747	7	44	clinical	clinical	ADJ
ajcp-747	7	45	trifecta	trifecta	NOUN
ajcp-747	7	46	of	of	ADP
ajcp-747	7	47	metabolic	metabolic	NOUN
ajcp-747	7	48	acidosis	acidosis	NOUN
ajcp-747	7	49	,	,	PUNCT
ajcp-747	7	50	hyperglycemia	hyperglycemia	NOUN
ajcp-747	7	51	,	,	PUNCT
ajcp-747	7	52	and	and	CCONJ
ajcp-747	7	53	elevated	elevated	ADJ
ajcp-747	7	54	ketone	ketone	NOUN
ajcp-747	7	55	bodies	body	NOUN
ajcp-747	7	56	in	in	ADP
ajcp-747	7	57	the	the	DET
ajcp-747	7	58	urine	urine	NOUN
ajcp-747	7	59	and	and	CCONJ
ajcp-747	7	60	blood	blood	NOUN
ajcp-747	7	61	is	be	AUX
ajcp-747	7	62	known	know	VERB
ajcp-747	7	63	as	as	ADP
ajcp-747	7	64	diabetic	diabetic	ADJ
ajcp-747	7	65	ketoacidosis	ketoacidosis	NOUN
ajcp-747	7	66	(	(	PUNCT
ajcp-747	7	67	dka	dka	NOUN
ajcp-747	7	68	)	)	PUNCT
ajcp-747	7	69	.	.	PUNCT
ajcp-747	8	1	euglycemic	euglycemic	PROPN
ajcp-747	8	2	dka	dka	PROPN
ajcp-747	8	3	(	(	PUNCT
ajcp-747	8	4	edka	edka	X
ajcp-747	8	5	)	)	PUNCT
ajcp-747	8	6	is	be	AUX
ajcp-747	8	7	the	the	DET
ajcp-747	8	8	precursor	precursor	NOUN
ajcp-747	8	9	to	to	ADP
ajcp-747	8	10	a	a	DET
ajcp-747	8	11	particular	particular	ADJ
ajcp-747	8	12	group	group	NOUN
ajcp-747	8	13	of	of	ADP
ajcp-747	8	14	people	people	NOUN
ajcp-747	8	15	whose	whose	DET
ajcp-747	8	16	blood	blood	NOUN
ajcp-747	8	17	glucose	glucose	NOUN
ajcp-747	8	18	levels	level	NOUN
ajcp-747	8	19	are	be	AUX
ajcp-747	8	20	between	between	ADP
ajcp-747	8	21	normal	normal	ADJ
ajcp-747	8	22	ranges	range	NOUN
ajcp-747	8	23	(	(	PUNCT
ajcp-747	8	24	nyenwe	nyenwe	NOUN
ajcp-747	8	25	&	&	CCONJ
ajcp-747	8	26	kitabchi	kitabchi	NOUN
ajcp-747	8	27	,	,	PUNCT
ajcp-747	8	28	2016	2016	NUM
ajcp-747	8	29	)	)	PUNCT
ajcp-747	8	30	.	.	PUNCT
ajcp-747	9	1	at	at	ADP
ajcp-747	9	2	the	the	DET
ajcp-747	9	3	presentation	presentation	NOUN
ajcp-747	9	4	time	time	NOUN
ajcp-747	9	5	,	,	PUNCT
ajcp-747	9	6	37	37	NUM
ajcp-747	9	7	out	out	ADP
ajcp-747	9	8	of	of	ADP
ajcp-747	9	9	211	211	NUM
ajcp-747	9	10	dka	dka	NOUN
ajcp-747	9	11	patients	patient	NOUN
ajcp-747	9	12	had	have	VERB
ajcp-747	9	13	normal	normal	ADJ
ajcp-747	9	14	blood	blood	NOUN
ajcp-747	9	15	sugar	sugar	NOUN
ajcp-747	9	16	levels	level	NOUN
ajcp-747	9	17	(	(	PUNCT
ajcp-747	9	18	300	300	NUM
ajcp-747	9	19	mg	mg	PROPN
ajcp-747	9	20	/	/	SYM
ajcp-747	9	21	dl	dl	PROPN
ajcp-747	9	22	)	)	PUNCT
ajcp-747	9	23	and	and	CCONJ
ajcp-747	9	24	a	a	DET
ajcp-747	9	25	plasma	plasma	NOUN
ajcp-747	9	26	bicarbonate	bicarbonate	NOUN
ajcp-747	9	27	level	level	NOUN
ajcp-747	9	28	of	of	ADP
ajcp-747	9	29	10	10	NUM
ajcp-747	9	30	mmol	mmol	NOUN
ajcp-747	9	31	/	/	SYM
ajcp-747	9	32	l.	l.	PROPN
ajcp-747	9	33	munro	munro	PROPN
ajcp-747	9	34	et	et	PROPN
ajcp-747	9	35	al	al	PROPN
ajcp-747	9	36	.	.	PROPN
ajcp-747	10	1	(	(	PUNCT
ajcp-747	10	2	1973	1973	NUM
ajcp-747	10	3	)	)	PUNCT
ajcp-747	10	4	were	be	AUX
ajcp-747	10	5	the	the	DET
ajcp-747	10	6	first	first	ADJ
ajcp-747	10	7	to	to	PART
ajcp-747	10	8	document	document	VERB
ajcp-747	10	9	this	this	DET
ajcp-747	10	10	phenomenon	phenomenon	NOUN
ajcp-747	10	11	.	.	PUNCT
ajcp-747	11	1	normoglycemia	normoglycemia	PROPN
ajcp-747	11	2	was	be	AUX
ajcp-747	11	3	interpreted	interpret	VERB
ajcp-747	11	4	as	as	ADP
ajcp-747	11	5	less	less	ADJ
ajcp-747	11	6	than	than	ADP
ajcp-747	11	7	250	250	NUM
ajcp-747	11	8	mg	mg	PROPN
ajcp-747	11	9	/	/	SYM
ajcp-747	11	10	dl	dl	PROPN
ajcp-747	11	11	.	.	PUNCT
ajcp-747	11	12	thus	thus	ADV
ajcp-747	11	13	,	,	PUNCT
ajcp-747	11	14	when	when	SCONJ
ajcp-747	11	15	serum	serum	NOUN
ajcp-747	11	16	glucose	glucose	NOUN
ajcp-747	11	17	levels	level	NOUN
ajcp-747	11	18	are	be	AUX
ajcp-747	11	19	below	below	ADP
ajcp-747	11	20	250	250	NUM
ajcp-747	11	21	mg	mg	PROPN
ajcp-747	11	22	/	/	SYM
ajcp-747	11	23	dl	dl	PROPN
ajcp-747	11	24	,	,	PUNCT
ajcp-747	11	25	edka	edka	PROPN
ajcp-747	11	26	is	be	AUX
ajcp-747	11	27	described	describe	VERB
ajcp-747	11	28	as	as	ADP
ajcp-747	11	29	a	a	DET
ajcp-747	11	30	trifecta	trifecta	NOUN
ajcp-747	11	31	that	that	PRON
ajcp-747	11	32	includes	include	VERB
ajcp-747	11	33	high	high	ADJ
ajcp-747	11	34	anion	anion	NOUN
ajcp-747	11	35	gap	gap	NOUN
ajcp-747	11	36	metabolic	metabolic	NOUN
ajcp-747	11	37	acidosis	acidosis	NOUN
ajcp-747	11	38	with	with	ADP
ajcp-747	11	39	positive	positive	ADJ
ajcp-747	11	40	urine	urine	NOUN
ajcp-747	11	41	and	and	CCONJ
ajcp-747	11	42	serum	serum	NOUN
ajcp-747	11	43	ketones	ketone	NOUN
ajcp-747	11	44	(	(	PUNCT
ajcp-747	11	45	kitabchi	kitabchi	NOUN
ajcp-747	11	46	et	et	PROPN
ajcp-747	11	47	al	al	PROPN
ajcp-747	11	48	.	.	PROPN
ajcp-747	11	49	,	,	PUNCT
ajcp-747	11	50	2009	2009	NUM
ajcp-747	11	51	)	)	PUNCT
ajcp-747	11	52	.	.	PUNCT
ajcp-747	12	1	one	one	NUM
ajcp-747	12	2	of	of	ADP
ajcp-747	12	3	the	the	DET
ajcp-747	12	4	most	most	ADV
ajcp-747	12	5	recent	recent	ADJ
ajcp-747	12	6	classes	class	NOUN
ajcp-747	12	7	of	of	ADP
ajcp-747	12	8	oral	oral	ADJ
ajcp-747	12	9	drugs	drug	NOUN
ajcp-747	12	10	for	for	ADP
ajcp-747	12	11	the	the	DET
ajcp-747	12	12	treatment	treatment	NOUN
ajcp-747	12	13	of	of	ADP
ajcp-747	12	14	t2	t2	NOUN
ajcp-747	12	15	dm	dm	NUM
ajcp-747	12	16	has	have	AUX
ajcp-747	12	17	been	be	AUX
ajcp-747	12	18	legalized	legalize	VERB
ajcp-747	12	19	,	,	PUNCT
ajcp-747	12	20	and	and	CCONJ
ajcp-747	12	21	it	it	PRON
ajcp-747	12	22	is	be	AUX
ajcp-747	12	23	called	call	VERB
ajcp-747	12	24	sodium	sodium	NOUN
ajcp-747	12	25	-	-	PUNCT
ajcp-747	12	26	glucose	glucose	NOUN
ajcp-747	12	27	cotransporter-2	cotransporter-2	NUM
ajcp-747	12	28	(	(	PUNCT
ajcp-747	12	29	sglt-2	sglt-2	NOUN
ajcp-747	12	30	)	)	PUNCT
ajcp-747	12	31	inhibitors	inhibitor	NOUN
ajcp-747	12	32	.	.	PUNCT
ajcp-747	13	1	they	they	PRON
ajcp-747	13	2	may	may	AUX
ajcp-747	13	3	be	be	AUX
ajcp-747	13	4	administered	administer	VERB
ajcp-747	13	5	to	to	ADP
ajcp-747	13	6	these	these	DET
ajcp-747	13	7	patients	patient	NOUN
ajcp-747	13	8	alone	alone	ADJ
ajcp-747	13	9	or	or	CCONJ
ajcp-747	13	10	with	with	ADP
ajcp-747	13	11	other	other	ADJ
ajcp-747	13	12	medications	medication	NOUN
ajcp-747	13	13	.	.	PUNCT
ajcp-747	14	1	they	they	PRON
ajcp-747	14	2	prevent	prevent	VERB
ajcp-747	14	3	glucose	glucose	NOUN
ajcp-747	14	4	reabsorption	reabsorption	NOUN
ajcp-747	14	5	in	in	ADP
ajcp-747	14	6	the	the	DET
ajcp-747	14	7	proximal	proximal	ADJ
ajcp-747	14	8	renal	renal	ADJ
ajcp-747	14	9	tubule	tubule	NOUN
ajcp-747	14	10	,	,	PUNCT
ajcp-747	14	11	which	which	PRON
ajcp-747	14	12	lowers	lower	VERB
ajcp-747	14	13	blood	blood	NOUN
ajcp-747	14	14	sugar	sugar	NOUN
ajcp-747	14	15	levels	level	NOUN
ajcp-747	14	16	(	(	PUNCT
ajcp-747	14	17	sarafidis	sarafidi	NOUN
ajcp-747	14	18	et	et	PROPN
ajcp-747	14	19	al	al	PROPN
ajcp-747	14	20	.	.	PROPN
ajcp-747	14	21	,	,	PUNCT
ajcp-747	14	22	2019	2019	NUM
ajcp-747	14	23	)	)	PUNCT
ajcp-747	14	24	.	.	PUNCT
ajcp-747	15	1	the	the	DET
ajcp-747	15	2	us	us	PROPN
ajcp-747	15	3	food	food	NOUN
ajcp-747	15	4	and	and	CCONJ
ajcp-747	15	5	drug	drug	PROPN
ajcp-747	15	6	administration	administration	PROPN
ajcp-747	15	7	(	(	PUNCT
ajcp-747	15	8	fda	fda	PROPN
ajcp-747	15	9	)	)	PUNCT
ajcp-747	15	10	officially	officially	ADV
ajcp-747	15	11	warned	warn	VERB
ajcp-747	15	12	patients	patient	NOUN
ajcp-747	15	13	using	use	VERB
ajcp-747	15	14	these	these	DET
ajcp-747	15	15	medications	medication	NOUN
ajcp-747	15	16	in	in	ADP
ajcp-747	15	17	2015	2015	NUM
ajcp-747	15	18	that	that	PRON
ajcp-747	15	19	they	they	PRON
ajcp-747	15	20	are	be	AUX
ajcp-747	15	21	at	at	ADP
ajcp-747	15	22	an	an	DET
ajcp-747	15	23	elevated	elevated	ADJ
ajcp-747	15	24	risk	risk	NOUN
ajcp-747	15	25	of	of	ADP
ajcp-747	15	26	developing	develop	VERB
ajcp-747	15	27	dka	dka	NOUN
ajcp-747	15	28	with	with	ADP
ajcp-747	15	29	unusually	unusually	ADV
ajcp-747	15	30	mild	mild	ADJ
ajcp-747	15	31	to	to	ADP
ajcp-747	15	32	moderate	moderate	ADJ
ajcp-747	15	33	glucose	glucose	NOUN
ajcp-747	15	34	spike	spike	NOUN
ajcp-747	15	35	,	,	PUNCT
ajcp-747	15	36	or	or	CCONJ
ajcp-747	15	37	edka	edka	X
ajcp-747	15	38	(	(	PUNCT
ajcp-747	15	39	do	do	PROPN
ajcp-747	15	40	,	,	PUNCT
ajcp-747	15	41	n.d	n.d	PROPN
ajcp-747	15	42	.	.	PROPN
ajcp-747	15	43	)	)	PUNCT
ajcp-747	15	44	.	.	PUNCT
ajcp-747	16	1	therefore	therefore	ADV
ajcp-747	16	2	,	,	PUNCT
ajcp-747	16	3	the	the	DET
ajcp-747	16	4	present	present	ADJ
ajcp-747	16	5	case	case	NOUN
ajcp-747	16	6	report	report	NOUN
ajcp-747	16	7	explores	explore	VERB
ajcp-747	16	8	the	the	DET
ajcp-747	16	9	rare	rare	ADJ
ajcp-747	16	10	presentation	presentation	NOUN
ajcp-747	16	11	of	of	ADP
ajcp-747	16	12	empagliflozin	empagliflozin	NOUN
ajcp-747	16	13	-	-	PUNCT
ajcp-747	16	14	induced	induce	VERB
ajcp-747	16	15	euglycemic	euglycemic	ADJ
ajcp-747	16	16	dka	dka	PROPN
ajcp-747	16	17	,	,	PUNCT
ajcp-747	16	18	(	(	PUNCT
ajcp-747	16	19	edka	edka	X
ajcp-747	16	20	)	)	PUNCT
ajcp-747	16	21	and	and	CCONJ
ajcp-747	16	22	acute	acute	PROPN
ajcp-747	16	23	pancreatitis	pancreatitis	PROPN
ajcp-747	16	24	in	in	ADP
ajcp-747	16	25	a	a	DET
ajcp-747	16	26	patient	patient	NOUN
ajcp-747	16	27	with	with	ADP
ajcp-747	16	28	t2	t2	NOUN
ajcp-747	16	29	dm	dm	NOUN
ajcp-747	16	30	just	just	ADV
ajcp-747	16	31	6	6	NUM
ajcp-747	16	32	days	day	NOUN
ajcp-747	16	33	after	after	ADP
ajcp-747	16	34	empagliflozin	empagliflozin	PROPN
ajcp-747	16	35	introduction	introduction	NOUN
ajcp-747	16	36	.	.	PUNCT
ajcp-747	17	1	abbreviations	abbreviation	NOUN
ajcp-747	17	2	dka	dka	NOUN
ajcp-747	17	3	=	=	NOUN
ajcp-747	17	4	diabetic	diabetic	ADJ
ajcp-747	17	5	ketoacidosis	ketoacidosis	NOUN
ajcp-747	17	6	,	,	PUNCT
ajcp-747	17	7	edka	edka	ADJ
ajcp-747	17	8	=	=	ADJ
ajcp-747	17	9	euglycemic	euglycemic	PROPN
ajcp-747	17	10	dka	dka	PROPN
ajcp-747	17	11	,	,	PUNCT
ajcp-747	17	12	sglt-2	sglt-2	NUM
ajcp-747	17	13	=	=	NOUN
ajcp-747	17	14	sodium	sodium	NOUN
ajcp-747	17	15	-	-	PUNCT
ajcp-747	17	16	glucose	glucose	NOUN
ajcp-747	17	17	cotransporter-2	cotransporter-2	NUM
ajcp-747	17	18	,	,	PUNCT
ajcp-747	17	19	fda=	fda=	NOUN
ajcp-747	17	20	food	food	NOUN
ajcp-747	17	21	and	and	CCONJ
ajcp-747	17	22	drug	drug	NOUN
ajcp-747	17	23	administration	administration	NOUN
ajcp-747	17	24	,	,	PUNCT
ajcp-747	17	25	vbg	vbg	PROPN
ajcp-747	17	26	=	=	ADJ
ajcp-747	17	27	venous	venous	ADJ
ajcp-747	17	28	blood	blood	NOUN
ajcp-747	17	29	gas	gas	NOUN
ajcp-747	17	30	,	,	PUNCT
ajcp-747	17	31	cva	cva	NOUN
ajcp-747	17	32	=	=	ADJ
ajcp-747	17	33	cerebral	cerebral	ADJ
ajcp-747	17	34	vascular	vascular	ADJ
ajcp-747	17	35	accident	accident	NOUN
ajcp-747	17	36	,	,	PUNCT
ajcp-747	17	37	hdu	hdu	PROPN
ajcp-747	17	38	=	=	ADJ
ajcp-747	17	39	high	high	ADJ
ajcp-747	17	40	dependency	dependency	NOUN
ajcp-747	17	41	unit	unit	NOUN
ajcp-747	17	42	,	,	PUNCT
ajcp-747	17	43	ct=	ct=	PROPN
ajcp-747	17	44	computed	compute	VERB
ajcp-747	17	45	tomography	tomography	NOUN
ajcp-747	17	46	methodology	methodology	NOUN
ajcp-747	17	47	case	case	NOUN
ajcp-747	17	48	presentation	presentation	NOUN
ajcp-747	17	49	a	a	DET
ajcp-747	17	50	presentation	presentation	NOUN
ajcp-747	17	51	from	from	ADP
ajcp-747	17	52	a	a	DET
ajcp-747	17	53	49	49	NUM
ajcp-747	17	54	-	-	PUNCT
ajcp-747	17	55	year	year	NOUN
ajcp-747	17	56	-	-	PUNCT
ajcp-747	17	57	old	old	ADJ
ajcp-747	17	58	man	man	NOUN
ajcp-747	17	59	nonsmoker	nonsmoker	NOUN
ajcp-747	17	60	with	with	ADP
ajcp-747	17	61	a	a	DET
ajcp-747	17	62	5	5	NUM
ajcp-747	17	63	-	-	PUNCT
ajcp-747	17	64	year	year	NOUN
ajcp-747	17	65	medical	medical	ADJ
ajcp-747	17	66	history	history	NOUN
ajcp-747	17	67	and	and	CCONJ
ajcp-747	17	68	worsening	worsen	VERB
ajcp-747	17	69	type	type	NOUN
ajcp-747	17	70	2	2	NUM
ajcp-747	17	71	diabetes	diabetes	NOUN
ajcp-747	17	72	mellitus	mellitus	NOUN
ajcp-747	17	73	due	due	ADP
ajcp-747	17	74	to	to	ADP
ajcp-747	17	75	poor	poor	ADJ
ajcp-747	17	76	compliance	compliance	NOUN
ajcp-747	17	77	was	be	AUX
ajcp-747	17	78	made	make	VERB
ajcp-747	17	79	to	to	ADP
ajcp-747	17	80	the	the	DET
ajcp-747	17	81	mediclinic	mediclinic	PROPN
ajcp-747	17	82	al	al	PROPN
ajcp-747	17	83	jowhara	jowhara	PROPN
ajcp-747	17	84	hospital	hospital	PROPN
ajcp-747	17	85	in	in	ADP
ajcp-747	17	86	the	the	DET
ajcp-747	17	87	united	united	PROPN
ajcp-747	17	88	arab	arab	PROPN
ajcp-747	17	89	emirates	emirates	PROPN
ajcp-747	17	90	.	.	PUNCT
ajcp-747	18	1	additionally	additionally	ADV
ajcp-747	18	2	,	,	PUNCT
ajcp-747	18	3	he	he	PRON
ajcp-747	18	4	had	have	VERB
ajcp-747	18	5	three	three	NUM
ajcp-747	18	6	days	day	NOUN
ajcp-747	18	7	’	'	PUNCT
ajcp-747	18	8	history	history	NOUN
ajcp-747	18	9	of	of	ADP
ajcp-747	18	10	upper	upper	ADJ
ajcp-747	18	11	abdominal	abdominal	ADJ
ajcp-747	18	12	pain	pain	NOUN
ajcp-747	18	13	,	,	PUNCT
ajcp-747	18	14	nausea	nausea	NOUN
ajcp-747	18	15	,	,	PUNCT
ajcp-747	18	16	and	and	CCONJ
ajcp-747	18	17	vomiting	vomiting	NOUN
ajcp-747	18	18	.	.	PUNCT
ajcp-747	19	1	he	he	PRON
ajcp-747	19	2	denies	deny	VERB
ajcp-747	19	3	fever	fever	NOUN
ajcp-747	19	4	,	,	PUNCT
ajcp-747	19	5	loose	loose	ADJ
ajcp-747	19	6	motion	motion	NOUN
ajcp-747	19	7	,	,	PUNCT
ajcp-747	19	8	melena	melena	NOUN
ajcp-747	19	9	,	,	PUNCT
ajcp-747	19	10	cough	cough	NOUN
ajcp-747	19	11	,	,	PUNCT
ajcp-747	19	12	or	or	CCONJ
ajcp-747	19	13	headache	headache	NOUN
ajcp-747	19	14	.	.	PUNCT
ajcp-747	20	1	six	six	NUM
ajcp-747	20	2	days	day	NOUN
ajcp-747	20	3	before	before	ADP
ajcp-747	20	4	the	the	DET
ajcp-747	20	5	presentation	presentation	NOUN
ajcp-747	20	6	,	,	PUNCT
ajcp-747	20	7	he	he	PRON
ajcp-747	20	8	suffered	suffer	VERB
ajcp-747	20	9	from	from	ADP
ajcp-747	20	10	cva	cva	PROPN
ajcp-747	20	11	with	with	ADP
ajcp-747	20	12	residual	residual	ADJ
ajcp-747	20	13	right	right	ADJ
ajcp-747	20	14	-	-	PUNCT
ajcp-747	20	15	sided	sided	ADJ
ajcp-747	20	16	weakness	weakness	NOUN
ajcp-747	20	17	.	.	PUNCT
ajcp-747	21	1	during	during	ADP
ajcp-747	21	2	his	his	PRON
ajcp-747	21	3	admittance	admittance	NOUN
ajcp-747	21	4	,	,	PUNCT
ajcp-747	21	5	he	he	PRON
ajcp-747	21	6	was	be	AUX
ajcp-747	21	7	initiated	initiate	VERB
ajcp-747	21	8	on	on	ADP
ajcp-747	21	9	aspirin	aspirin	NOUN
ajcp-747	21	10	,	,	PUNCT
ajcp-747	21	11	clopidogrel	clopidogrel	NOUN
ajcp-747	21	12	,	,	PUNCT
ajcp-747	21	13	atorvastatin	atorvastatin	PROPN
ajcp-747	21	14	40	40	NUM
ajcp-747	21	15	mg	mg	PROPN
ajcp-747	21	16	,	,	PUNCT
ajcp-747	21	17	lisinopril	lisinopril	NOUN
ajcp-747	21	18	5	5	NUM
ajcp-747	21	19	mg	mg	PROPN
ajcp-747	21	20	,	,	PUNCT
ajcp-747	21	21	linagliptin	linagliptin	PROPN
ajcp-747	21	22	/	/	SYM
ajcp-747	21	23	metformin	metformin	NOUN
ajcp-747	21	24	5mg/1000	5mg/1000	NUM
ajcp-747	21	25	mg	mg	NOUN
ajcp-747	21	26	once	once	ADV
ajcp-747	21	27	,	,	PUNCT
ajcp-747	21	28	and	and	CCONJ
ajcp-747	21	29	empagliflozin	empagliflozin	PROPN
ajcp-747	21	30	25	25	NUM
ajcp-747	21	31	mg	mg	PROPN
ajcp-747	21	32	.	.	PUNCT
ajcp-747	22	1	the	the	DET
ajcp-747	22	2	initial	initial	ADJ
ajcp-747	22	3	observational	observational	ADJ
ajcp-747	22	4	analysis	analysis	NOUN
ajcp-747	22	5	revealed	reveal	VERB
ajcp-747	22	6	that	that	SCONJ
ajcp-747	22	7	he	he	PRON
ajcp-747	22	8	was	be	AUX
ajcp-747	22	9	tachypneic	tachypneic	ADJ
ajcp-747	22	10	but	but	CCONJ
ajcp-747	22	11	otherwise	otherwise	ADV
ajcp-747	22	12	vitally	vitally	ADV
ajcp-747	22	13	normal	normal	ADJ
ajcp-747	22	14	.	.	PUNCT
ajcp-747	23	1	other	other	ADJ
ajcp-747	23	2	vital	vital	ADJ
ajcp-747	23	3	signs	sign	NOUN
ajcp-747	23	4	include	include	VERB
ajcp-747	23	5	his	his	PRON
ajcp-747	23	6	rbg	rbg	NOUN
ajcp-747	23	7	as	as	ADP
ajcp-747	23	8	11.1	11.1	NUM
ajcp-747	23	9	mmol	mmol	NOUN
ajcp-747	23	10	/	/	SYM
ajcp-747	23	11	l	l	NOUN
ajcp-747	23	12	,	,	PUNCT
ajcp-747	23	13	dry	dry	ADJ
ajcp-747	23	14	mucous	mucous	ADJ
ajcp-747	23	15	membranes	membrane	NOUN
ajcp-747	23	16	,	,	PUNCT
ajcp-747	23	17	but	but	CCONJ
ajcp-747	23	18	normal	normal	ADJ
ajcp-747	23	19	capillary	capillary	ADJ
ajcp-747	23	20	refill	refill	NOUN
ajcp-747	23	21	time	time	NOUN
ajcp-747	23	22	.	.	PUNCT
ajcp-747	24	1	additionally	additionally	ADV
ajcp-747	24	2	,	,	PUNCT
ajcp-747	24	3	on	on	ADP
ajcp-747	24	4	clinical	clinical	ADJ
ajcp-747	24	5	assessment	assessment	NOUN
ajcp-747	24	6	,	,	PUNCT
ajcp-747	24	7	there	there	PRON
ajcp-747	24	8	was	be	VERB
ajcp-747	24	9	right	right	ADV
ajcp-747	24	10	lower	low	ADJ
ajcp-747	24	11	limb	limb	NOUN
ajcp-747	24	12	’s	’s	PART
ajcp-747	24	13	minor	minor	ADJ
ajcp-747	24	14	motor	motor	NOUN
ajcp-747	24	15	impairment	impairment	NOUN
ajcp-747	24	16	,	,	PUNCT
ajcp-747	24	17	intact	intact	ADJ
ajcp-747	24	18	sensory	sensory	ADJ
ajcp-747	24	19	functions	function	NOUN
ajcp-747	24	20	,	,	PUNCT
ajcp-747	24	21	normal	normal	ADJ
ajcp-747	24	22	reflexes	reflex	NOUN
ajcp-747	24	23	,	,	PUNCT
ajcp-747	24	24	and	and	CCONJ
ajcp-747	24	25	normal	normal	ADJ
ajcp-747	24	26	cranial	cranial	ADJ
ajcp-747	24	27	and	and	CCONJ
ajcp-747	24	28	cerebellar	cerebellar	ADJ
ajcp-747	24	29	functions	function	NOUN
ajcp-747	24	30	were	be	AUX
ajcp-747	24	31	notable	notable	ADJ
ajcp-747	24	32	.	.	PUNCT
ajcp-747	25	1	his	his	PRON
ajcp-747	25	2	venous	venous	ADJ
ajcp-747	25	3	blood	blood	NOUN
ajcp-747	25	4	gases	gas	NOUN
ajcp-747	25	5	(	(	PUNCT
ajcp-747	25	6	vbg	vbg	PROPN
ajcp-747	25	7	)	)	PUNCT
ajcp-747	25	8	represented	represent	VERB
ajcp-747	25	9	ph	ph	NOUN
ajcp-747	25	10	7.121	7.121	NUM
ajcp-747	25	11	,	,	PUNCT
ajcp-747	25	12	hco3	hco3	PROPN
ajcp-747	25	13	9.6	9.6	NUM
ajcp-747	25	14	mmol	mmol	PROPN
ajcp-747	25	15	/	/	SYM
ajcp-747	25	16	l	l	PROPN
ajcp-747	25	17	,	,	PUNCT
ajcp-747	25	18	pco2	pco2	NOUN
ajcp-747	25	19	25.4	25.4	NUM
ajcp-747	25	20	mmhg	mmhg	NOUN
ajcp-747	25	21	,	,	PUNCT
ajcp-747	25	22	lactate	lactate	NOUN
ajcp-747	25	23	2.1	2.1	NUM
ajcp-747	25	24	mmol	mmol	NOUN
ajcp-747	25	25	/	/	SYM
ajcp-747	25	26	l	l	NOUN
ajcp-747	25	27	,	,	PUNCT
ajcp-747	25	28	na	na	PROPN
ajcp-747	25	29	128	128	NUM
ajcp-747	25	30	mmol	mmol	NOUN
ajcp-747	25	31	/	/	SYM
ajcp-747	25	32	l	l	NOUN
ajcp-747	25	33	,	,	PUNCT
ajcp-747	25	34	cl	cl	NOUN
ajcp-747	25	35	101	101	NUM
ajcp-747	25	36	mmol	mmol	NOUN
ajcp-747	25	37	/	/	SYM
ajcp-747	25	38	l	l	NOUN
ajcp-747	25	39	,	,	PUNCT
ajcp-747	25	40	and	and	CCONJ
ajcp-747	25	41	k	k	PROPN
ajcp-747	25	42	5.2	5.2	NUM
ajcp-747	25	43	mmol	mmol	NOUN
ajcp-747	25	44	/	/	SYM
ajcp-747	25	45	l	l	NOUN
ajcp-747	25	46	and	and	CCONJ
ajcp-747	25	47	urine	urine	NOUN
ajcp-747	25	48	showed	show	VERB
ajcp-747	25	49	ketone	ketone	NOUN
ajcp-747	25	50	+3	+3	PUNCT
ajcp-747	25	51	suggestive	suggestive	ADJ
ajcp-747	25	52	of	of	ADP
ajcp-747	25	53	high	high	ADJ
ajcp-747	25	54	anion	anion	NOUN
ajcp-747	25	55	gap	gap	NOUN
ajcp-747	25	56	(	(	PUNCT
ajcp-747	25	57	17.4	17.4	NUM
ajcp-747	25	58	)	)	PUNCT
ajcp-747	25	59	,	,	PUNCT
ajcp-747	25	60	severe	severe	ADJ
ajcp-747	25	61	metabolic	metabolic	NOUN
ajcp-747	25	62	ketoacidosis	ketoacidosis	NOUN
ajcp-747	25	63	and	and	CCONJ
ajcp-747	25	64	his	his	PRON
ajcp-747	25	65	hba1c	hba1c	NOUN
ajcp-747	25	66	was	be	AUX
ajcp-747	25	67	8.1	8.1	NUM
ajcp-747	25	68	%	%	NOUN
ajcp-747	25	69	.	.	PUNCT
ajcp-747	26	1	the	the	DET
ajcp-747	26	2	patient	patient	NOUN
ajcp-747	26	3	’s	’s	PART
ajcp-747	26	4	lipase	lipase	NOUN
ajcp-747	26	5	and	and	CCONJ
ajcp-747	26	6	amylase	amylase	NOUN
ajcp-747	26	7	were	be	AUX
ajcp-747	26	8	elevated	elevate	VERB
ajcp-747	26	9	at	at	ADP
ajcp-747	26	10	440	440	NUM
ajcp-747	26	11	u	u	NOUN
ajcp-747	26	12	/	/	SYM
ajcp-747	26	13	l	l	NOUN
ajcp-747	26	14	and	and	CCONJ
ajcp-747	26	15	354	354	NUM
ajcp-747	26	16	u	u	NOUN
ajcp-747	26	17	/	/	SYM
ajcp-747	26	18	l	l	NOUN
ajcp-747	26	19	,	,	PUNCT
ajcp-747	26	20	respectively	respectively	ADV
ajcp-747	26	21	,	,	PUNCT
ajcp-747	26	22	compatible	compatible	ADJ
ajcp-747	26	23	with	with	ADP
ajcp-747	26	24	acute	acute	ADJ
ajcp-747	26	25	pancreatitis	pancreatitis	PROPN
ajcp-747	26	26	(	(	PUNCT
ajcp-747	26	27	table	table	NOUN
ajcp-747	26	28	1	1	NUM
ajcp-747	26	29	)	)	PUNCT
ajcp-747	26	30	.	.	PUNCT
ajcp-747	27	1	ecg	ecg	PROPN
ajcp-747	27	2	assessment	assessment	NOUN
ajcp-747	27	3	was	be	AUX
ajcp-747	27	4	reported	report	VERB
ajcp-747	27	5	normal	normal	ADJ
ajcp-747	27	6	,	,	PUNCT
ajcp-747	27	7	as	as	ADV
ajcp-747	27	8	well	well	ADV
ajcp-747	27	9	as	as	ADP
ajcp-747	27	10	chest	chest	NOUN
ajcp-747	27	11	x	x	NOUN
ajcp-747	27	12	-	-	NOUN
ajcp-747	27	13	ray	ray	NOUN
ajcp-747	27	14	and	and	CCONJ
ajcp-747	27	15	abdominal	abdominal	ADJ
ajcp-747	27	16	https://doi.org/10.54536/ajcp.v1i2.747	https://doi.org/10.54536/ajcp.v1i2.747	NOUN
ajcp-747	27	17	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-747	27	18	mailto	mailto	NOUN
ajcp-747	27	19	:	:	PUNCT
ajcp-747	27	20	dr.yassersadawey%40gmail.com?subject=	dr.yassersadawey%40gmail.com?subject=	PROPN
ajcp-747	27	21	pa	pa	PROPN
ajcp-747	27	22	ge	ge	PROPN
ajcp-747	27	23	2	2	NUM
ajcp-747	27	24	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-747	27	25	am	be	AUX
ajcp-747	27	26	.	.	PUNCT
ajcp-747	28	1	j.	j.	PROPN
ajcp-747	28	2	chem	chem	PROPN
ajcp-747	28	3	.	.	PUNCT
ajcp-747	29	1	pharm	pharm	PROPN
ajcp-747	29	2	.	.	PUNCT
ajcp-747	30	1	1(2	1(2	NUM
ajcp-747	30	2	)	)	PUNCT
ajcp-747	30	3	1	1	NUM
ajcp-747	30	4	-	-	SYM
ajcp-747	30	5	4	4	NUM
ajcp-747	30	6	,	,	PUNCT
ajcp-747	30	7	2022	2022	NUM
ajcp-747	30	8	figure	figure	NOUN
ajcp-747	30	9	1	1	NUM
ajcp-747	30	10	:	:	PUNCT
ajcp-747	30	11	axial	axial	ADJ
ajcp-747	30	12	and	and	CCONJ
ajcp-747	30	13	coronal	coronal	ADJ
ajcp-747	30	14	ct	ct	NUM
ajcp-747	30	15	images	image	NOUN
ajcp-747	30	16	in	in	ADP
ajcp-747	30	17	venous	venous	ADJ
ajcp-747	30	18	phase	phase	NOUN
ajcp-747	30	19	showing	show	VERB
ajcp-747	30	20	minimal	minimal	ADJ
ajcp-747	30	21	peripancreatic	peripancreatic	ADJ
ajcp-747	30	22	fat	fat	NOUN
ajcp-747	30	23	stranding	stranding	NOUN
ajcp-747	30	24	around	around	ADP
ajcp-747	30	25	the	the	DET
ajcp-747	30	26	head	head	NOUN
ajcp-747	30	27	and	and	CCONJ
ajcp-747	30	28	body	body	NOUN
ajcp-747	30	29	as	as	ADP
ajcp-747	30	30	early	early	ADJ
ajcp-747	30	31	features	feature	NOUN
ajcp-747	30	32	of	of	ADP
ajcp-747	30	33	pancreatitis	pancreatitis	NOUN
ajcp-747	30	34	.	.	PUNCT
ajcp-747	31	1	no	no	DET
ajcp-747	31	2	peripancreatic	peripancreatic	ADJ
ajcp-747	31	3	fluid	fluid	NOUN
ajcp-747	31	4	.	.	PUNCT
ajcp-747	31	5	ultrasound	ultrasound	PROPN
ajcp-747	31	6	.	.	PUNCT
ajcp-747	32	1	abdomen	abdomen	PROPN
ajcp-747	32	2	ct	ct	PROPN
ajcp-747	32	3	showed	show	VERB
ajcp-747	32	4	mild	mild	ADJ
ajcp-747	32	5	enlargement	enlargement	NOUN
ajcp-747	32	6	of	of	ADP
ajcp-747	32	7	pancreatic	pancreatic	ADJ
ajcp-747	32	8	head	head	NOUN
ajcp-747	32	9	with	with	ADP
ajcp-747	32	10	subtle	subtle	ADJ
ajcp-747	32	11	peri	peri	NOUN
ajcp-747	32	12	-	-	PUNCT
ajcp-747	32	13	pancreatic	pancreatic	ADJ
ajcp-747	32	14	fat	fat	NOUN
ajcp-747	32	15	stranding	stranding	NOUN
ajcp-747	32	16	,	,	PUNCT
ajcp-747	32	17	a	a	DET
ajcp-747	32	18	picture	picture	NOUN
ajcp-747	32	19	of	of	ADP
ajcp-747	32	20	mild	mild	ADJ
ajcp-747	32	21	pancreatitis	pancreatitis	NOUN
ajcp-747	32	22	.	.	PUNCT
ajcp-747	33	1	the	the	DET
ajcp-747	33	2	patient	patient	NOUN
ajcp-747	33	3	was	be	AUX
ajcp-747	33	4	admitted	admit	VERB
ajcp-747	33	5	to	to	ADP
ajcp-747	33	6	hdu	hdu	PROPN
ajcp-747	33	7	for	for	ADP
ajcp-747	33	8	management	management	NOUN
ajcp-747	33	9	of	of	ADP
ajcp-747	33	10	edka	edka	ADJ
ajcp-747	33	11	,	,	PUNCT
ajcp-747	33	12	linagliptin	linagliptin	ADJ
ajcp-747	33	13	/	/	SYM
ajcp-747	33	14	metformin	metformin	NOUN
ajcp-747	33	15	,	,	PUNCT
ajcp-747	33	16	empagliflozin	empagliflozin	PROPN
ajcp-747	33	17	were	be	AUX
ajcp-747	33	18	held	hold	VERB
ajcp-747	33	19	,	,	PUNCT
ajcp-747	33	20	and	and	CCONJ
ajcp-747	33	21	intravenous	intravenous	ADJ
ajcp-747	33	22	fluids	fluid	NOUN
ajcp-747	33	23	and	and	CCONJ
ajcp-747	33	24	insulin	insulin	NOUN
ajcp-747	33	25	infusion	infusion	NOUN
ajcp-747	33	26	were	be	AUX
ajcp-747	33	27	initiated	initiate	VERB
ajcp-747	33	28	with	with	ADP
ajcp-747	33	29	repeated	repeat	VERB
ajcp-747	33	30	vbg	vbg	NOUN
ajcp-747	33	31	every	every	DET
ajcp-747	33	32	2	2	NUM
ajcp-747	33	33	hours	hour	NOUN
ajcp-747	33	34	.	.	PUNCT
ajcp-747	34	1	his	his	PRON
ajcp-747	34	2	ph	ph	NOUN
ajcp-747	34	3	normalized	normalize	VERB
ajcp-747	34	4	,	,	PUNCT
ajcp-747	34	5	ketonuria	ketonuria	PROPN
ajcp-747	34	6	improved	improve	VERB
ajcp-747	34	7	,	,	PUNCT
ajcp-747	34	8	and	and	CCONJ
ajcp-747	34	9	the	the	DET
ajcp-747	34	10	anion	anion	NOUN
ajcp-747	34	11	gap	gap	NOUN
ajcp-747	34	12	closed	close	VERB
ajcp-747	34	13	.	.	PUNCT
ajcp-747	35	1	he	he	PRON
ajcp-747	35	2	made	make	VERB
ajcp-747	35	3	a	a	DET
ajcp-747	35	4	good	good	ADJ
ajcp-747	35	5	recovery	recovery	NOUN
ajcp-747	35	6	with	with	ADP
ajcp-747	35	7	normalizing	normalize	VERB
ajcp-747	35	8	pancreatic	pancreatic	ADJ
ajcp-747	35	9	enzymes	enzyme	NOUN
ajcp-747	35	10	and	and	CCONJ
ajcp-747	35	11	improved	improved	ADJ
ajcp-747	35	12	symptoms	symptom	NOUN
ajcp-747	35	13	.	.	PUNCT
ajcp-747	36	1	once	once	SCONJ
ajcp-747	36	2	he	he	PRON
ajcp-747	36	3	could	could	AUX
ajcp-747	36	4	tolerate	tolerate	VERB
ajcp-747	36	5	normal	normal	ADJ
ajcp-747	36	6	oral	oral	ADJ
ajcp-747	36	7	intake	intake	NOUN
ajcp-747	36	8	,	,	PUNCT
ajcp-747	36	9	he	he	PRON
ajcp-747	36	10	shifted	shift	VERB
ajcp-747	36	11	to	to	ADP
ajcp-747	36	12	sitagliptin	sitagliptin	NOUN
ajcp-747	36	13	/	/	SYM
ajcp-747	36	14	metformin	metformin	NOUN
ajcp-747	36	15	100/1000	100/1000	NUM
ajcp-747	36	16	mg	mg	NOUN
ajcp-747	36	17	and	and	CCONJ
ajcp-747	36	18	gliclazide	gliclazide	VERB
ajcp-747	36	19	120	120	NUM
ajcp-747	36	20	mg	mg	NOUN
ajcp-747	36	21	.	.	PUNCT
ajcp-747	37	1	after	after	ADP
ajcp-747	37	2	dietary	dietary	ADJ
ajcp-747	37	3	consultation	consultation	NOUN
ajcp-747	37	4	and	and	CCONJ
ajcp-747	37	5	education	education	NOUN
ajcp-747	37	6	,	,	PUNCT
ajcp-747	37	7	he	he	PRON
ajcp-747	37	8	was	be	AUX
ajcp-747	37	9	discharged	discharge	VERB
ajcp-747	37	10	.	.	PUNCT
ajcp-747	38	1	upon	upon	SCONJ
ajcp-747	38	2	follow	follow	VERB
ajcp-747	38	3	-	-	PUNCT
ajcp-747	38	4	up	up	ADP
ajcp-747	38	5	visits	visit	NOUN
ajcp-747	38	6	,	,	PUNCT
ajcp-747	38	7	he	he	PRON
ajcp-747	38	8	was	be	AUX
ajcp-747	38	9	clinically	clinically	ADV
ajcp-747	38	10	stable	stable	ADJ
ajcp-747	38	11	,	,	PUNCT
ajcp-747	38	12	tolerating	tolerate	VERB
ajcp-747	38	13	his	his	PRON
ajcp-747	38	14	medications	medication	NOUN
ajcp-747	38	15	with	with	ADP
ajcp-747	38	16	good	good	ADJ
ajcp-747	38	17	glycemic	glycemic	ADJ
ajcp-747	38	18	control	control	NOUN
ajcp-747	38	19	,	,	PUNCT
ajcp-747	38	20	and	and	CCONJ
ajcp-747	38	21	his	his	PRON
ajcp-747	38	22	hba1c	hba1c	NOUN
ajcp-747	38	23	became	become	VERB
ajcp-747	38	24	6.2	6.2	NUM
ajcp-747	38	25	%	%	NOUN
ajcp-747	38	26	.	.	PUNCT
ajcp-747	39	1	using	use	VERB
ajcp-747	39	2	the	the	DET
ajcp-747	39	3	naranjo	naranjo	PROPN
ajcp-747	39	4	algorithm	algorithm	NOUN
ajcp-747	39	5	of	of	ADP
ajcp-747	39	6	adverse	adverse	ADJ
ajcp-747	39	7	drug	drug	NOUN
ajcp-747	39	8	reactions	reaction	NOUN
ajcp-747	39	9	,	,	PUNCT
ajcp-747	39	10	we	we	PRON
ajcp-747	39	11	concluded	conclude	VERB
ajcp-747	39	12	that	that	SCONJ
ajcp-747	39	13	empagliflozin	empagliflozin	PROPN
ajcp-747	39	14	was	be	AUX
ajcp-747	39	15	the	the	DET
ajcp-747	39	16	most	most	ADV
ajcp-747	39	17	likely	likely	ADJ
ajcp-747	39	18	culprit	culprit	NOUN
ajcp-747	39	19	for	for	ADP
ajcp-747	39	20	his	his	PRON
ajcp-747	39	21	pancreatitis	pancreatitis	NOUN
ajcp-747	39	22	.	.	PUNCT
ajcp-747	40	1	table	table	NOUN
ajcp-747	40	2	1	1	NUM
ajcp-747	40	3	:	:	PUNCT
ajcp-747	40	4	initial	initial	ADJ
ajcp-747	40	5	and	and	CCONJ
ajcp-747	40	6	follow	follow	VERB
ajcp-747	40	7	up	up	ADP
ajcp-747	40	8	laboratory	laboratory	NOUN
ajcp-747	40	9	values	value	NOUN
ajcp-747	40	10	parameters	parameter	NOUN
ajcp-747	40	11	initial	initial	ADJ
ajcp-747	40	12	day1	day1	NOUN
ajcp-747	40	13	day	day	NOUN
ajcp-747	40	14	2	2	NUM
ajcp-747	40	15	on	on	ADP
ajcp-747	40	16	discharge	discharge	VERB
ajcp-747	40	17	venous	venous	ADJ
ajcp-747	40	18	ph	ph	NOUN
ajcp-747	40	19	(	(	PUNCT
ajcp-747	40	20	7.36–7.44	7.36–7.44	NOUN
ajcp-747	40	21	)	)	PUNCT
ajcp-747	40	22	7.121	7.121	NUM
ajcp-747	40	23	7.224	7.224	NUM
ajcp-747	40	24	7.36	7.36	NUM
ajcp-747	40	25	7.439	7.439	NUM
ajcp-747	40	26	serum	serum	NOUN
ajcp-747	40	27	bicarbonate	bicarbonate	NOUN
ajcp-747	40	28	(	(	PUNCT
ajcp-747	40	29	21–28	21–28	NUM
ajcp-747	40	30	mmol	mmol	NOUN
ajcp-747	40	31	/	/	SYM
ajcp-747	40	32	l	l	NOUN
ajcp-747	40	33	)	)	PUNCT
ajcp-747	40	34	9.6	9.6	NUM
ajcp-747	40	35	11.6	11.6	NUM
ajcp-747	40	36	19.2	19.2	NUM
ajcp-747	40	37	25.7	25.7	NUM
ajcp-747	40	38	pco2	pco2	NOUN
ajcp-747	40	39	(	(	PUNCT
ajcp-747	40	40	35	35	NUM
ajcp-747	40	41	-	-	SYM
ajcp-747	40	42	45mmhg	45mmhg	NUM
ajcp-747	40	43	)	)	PUNCT
ajcp-747	40	44	25.4	25.4	NUM
ajcp-747	40	45	22.5	22.5	NUM
ajcp-747	40	46	33	33	NUM
ajcp-747	40	47	39.9	39.9	NUM
ajcp-747	40	48	serum	serum	NOUN
ajcp-747	40	49	lactate	lactate	NOUN
ajcp-747	40	50	(	(	PUNCT
ajcp-747	40	51	0.5–1.4	0.5–1.4	NOUN
ajcp-747	40	52	mmol	mmol	NOUN
ajcp-747	40	53	/	/	SYM
ajcp-747	40	54	l	l	NOUN
ajcp-747	40	55	)	)	PUNCT
ajcp-747	40	56	2.1	2.1	NUM
ajcp-747	40	57	1.7	1.7	NUM
ajcp-747	40	58	1.6	1.6	NUM
ajcp-747	40	59	1.7	1.7	NUM
ajcp-747	40	60	serum	serum	NOUN
ajcp-747	40	61	sodium	sodium	NOUN
ajcp-747	40	62	(	(	PUNCT
ajcp-747	40	63	135–145	135–145	NUM
ajcp-747	40	64	meq	meq	NOUN
ajcp-747	40	65	/	/	SYM
ajcp-747	40	66	l	l	NOUN
ajcp-747	40	67	)	)	PUNCT
ajcp-747	40	68	128	128	NUM
ajcp-747	40	69	132	132	NUM
ajcp-747	40	70	134	134	NUM
ajcp-747	40	71	134	134	NUM
ajcp-747	40	72	chloride	chloride	NOUN
ajcp-747	40	73	(	(	PUNCT
ajcp-747	40	74	98–107	98–107	PROPN
ajcp-747	40	75	mmol	mmol	NOUN
ajcp-747	40	76	/	/	SYM
ajcp-747	40	77	l	l	NOUN
ajcp-747	40	78	)	)	PUNCT
ajcp-747	40	79	101	101	NUM
ajcp-747	40	80	108	108	NUM
ajcp-747	40	81	103	103	NUM
ajcp-747	40	82	99	99	NUM
ajcp-747	40	83	serum	serum	NOUN
ajcp-747	40	84	potassium	potassium	NOUN
ajcp-747	40	85	(	(	PUNCT
ajcp-747	40	86	3.5–5.0	3.5–5.0	NUM
ajcp-747	40	87	mmol	mmol	NOUN
ajcp-747	40	88	/	/	SYM
ajcp-747	40	89	l	l	NOUN
ajcp-747	40	90	)	)	PUNCT
ajcp-747	40	91	5.2	5.2	NUM
ajcp-747	40	92	5.7	5.7	NUM
ajcp-747	40	93	4.1	4.1	NUM
ajcp-747	40	94	3.8	3.8	NUM
ajcp-747	40	95	anion	anion	NOUN
ajcp-747	40	96	gap	gap	NOUN
ajcp-747	40	97	(	(	PUNCT
ajcp-747	40	98	8–16	8–16	PROPN
ajcp-747	40	99	mmol	mmol	NOUN
ajcp-747	40	100	/	/	SYM
ajcp-747	40	101	l	l	NOUN
ajcp-747	40	102	)	)	PUNCT
ajcp-747	40	103	17.4	17.4	NUM
ajcp-747	40	104	12.4	12.4	NUM
ajcp-747	40	105	11.8	11.8	NUM
ajcp-747	40	106	9.3	9.3	NUM
ajcp-747	40	107	urine	urine	NOUN
ajcp-747	40	108	ketone	ketone	NOUN
ajcp-747	40	109	(	(	PUNCT
ajcp-747	40	110	negative	negative	ADJ
ajcp-747	40	111	)	)	PUNCT
ajcp-747	41	1	+	+	ADJ
ajcp-747	41	2	+	+	ADJ
ajcp-747	41	3	+	+	ADJ
ajcp-747	41	4	+	+	ADJ
ajcp-747	41	5	+	+	ADJ
ajcp-747	41	6	+	+	NUM
ajcp-747	41	7	ve	ve	AUX
ajcp-747	41	8	hba1c	hba1c	PROPN
ajcp-747	41	9	(	(	PUNCT
ajcp-747	41	10	%	%	INTJ
ajcp-747	41	11	)	)	PUNCT
ajcp-747	41	12	8.1	8.1	NUM
ajcp-747	41	13	lipase	lipase	NOUN
ajcp-747	41	14	(	(	PUNCT
ajcp-747	41	15	0	0	NUM
ajcp-747	41	16	-	-	PUNCT
ajcp-747	41	17	160u	160u	NUM
ajcp-747	41	18	/	/	SYM
ajcp-747	41	19	l	l	NOUN
ajcp-747	41	20	)	)	PUNCT
ajcp-747	41	21	440	440	NUM
ajcp-747	41	22	u	u	NOUN
ajcp-747	41	23	/	/	SYM
ajcp-747	41	24	l	l	PROPN
ajcp-747	41	25	117	117	NUM
ajcp-747	41	26	110	110	NUM
ajcp-747	41	27	amylase	amylase	NOUN
ajcp-747	41	28	(	(	PUNCT
ajcp-747	41	29	23–85	23–85	NUM
ajcp-747	41	30	u	u	NOUN
ajcp-747	41	31	/	/	SYM
ajcp-747	41	32	l	l	NOUN
ajcp-747	41	33	)	)	PUNCT
ajcp-747	41	34	354u	354u	PROPN
ajcp-747	41	35	/	/	SYM
ajcp-747	41	36	l	l	NOUN
ajcp-747	41	37	123	123	NUM
ajcp-747	41	38	78	78	NUM
ajcp-747	41	39	discussion	discussion	NOUN
ajcp-747	41	40	dka	dka	PROPN
ajcp-747	41	41	occurs	occur	VERB
ajcp-747	41	42	in	in	ADP
ajcp-747	41	43	1.34	1.34	NUM
ajcp-747	41	44	/	/	SYM
ajcp-747	41	45	million	million	NUM
ajcp-747	41	46	t2d	t2d	NOUN
ajcp-747	41	47	patients	patient	NOUN
ajcp-747	41	48	annually	annually	ADV
ajcp-747	41	49	(	(	PUNCT
ajcp-747	41	50	jensen	jensen	PROPN
ajcp-747	41	51	et	et	PROPN
ajcp-747	41	52	al	al	PROPN
ajcp-747	41	53	.	.	PROPN
ajcp-747	41	54	,	,	PUNCT
ajcp-747	41	55	2017	2017	NUM
ajcp-747	41	56	)	)	PUNCT
ajcp-747	41	57	.	.	PUNCT
ajcp-747	42	1	in	in	ADP
ajcp-747	42	2	contrast	contrast	NOUN
ajcp-747	42	3	,	,	PUNCT
ajcp-747	42	4	it	it	PRON
ajcp-747	42	5	is	be	AUX
ajcp-747	42	6	unknown	unknown	ADJ
ajcp-747	42	7	how	how	SCONJ
ajcp-747	42	8	often	often	ADV
ajcp-747	42	9	euglycemic	euglycemic	ADJ
ajcp-747	42	10	dka	dka	PROPN
ajcp-747	42	11	will	will	AUX
ajcp-747	42	12	occur	occur	VERB
ajcp-747	42	13	.	.	PUNCT
ajcp-747	43	1	the	the	DET
ajcp-747	43	2	uncommon	uncommon	ADJ
ajcp-747	43	3	occurrence	occurrence	NOUN
ajcp-747	43	4	of	of	ADP
ajcp-747	43	5	euglycemic	euglycemic	PROPN
ajcp-747	43	6	dka	dka	PROPN
ajcp-747	43	7	may	may	AUX
ajcp-747	43	8	cause	cause	VERB
ajcp-747	43	9	a	a	DET
ajcp-747	43	10	deferment	deferment	NOUN
ajcp-747	43	11	in	in	ADP
ajcp-747	43	12	care	care	NOUN
ajcp-747	43	13	and	and	CCONJ
ajcp-747	43	14	prognosis	prognosis	NOUN
ajcp-747	43	15	,	,	PUNCT
ajcp-747	43	16	which	which	PRON
ajcp-747	43	17	might	might	AUX
ajcp-747	43	18	have	have	VERB
ajcp-747	43	19	significant	significant	ADJ
ajcp-747	43	20	or	or	CCONJ
ajcp-747	43	21	fatal	fatal	ADJ
ajcp-747	43	22	consequences(calçada	consequences(calçada	PROPN
ajcp-747	43	23	et	et	NOUN
ajcp-747	43	24	al	al	PROPN
ajcp-747	43	25	.	.	PROPN
ajcp-747	43	26	,	,	PUNCT
ajcp-747	43	27	2021	2021	NUM
ajcp-747	43	28	)	)	PUNCT
ajcp-747	43	29	.	.	PUNCT
ajcp-747	44	1	a	a	DET
ajcp-747	44	2	recent	recent	ADJ
ajcp-747	44	3	family	family	NOUN
ajcp-747	44	4	of	of	ADP
ajcp-747	44	5	anti	anti	ADJ
ajcp-747	44	6	-	-	ADJ
ajcp-747	44	7	diabetic	diabetic	ADJ
ajcp-747	44	8	medications	medication	NOUN
ajcp-747	44	9	known	know	VERB
ajcp-747	44	10	as	as	ADP
ajcp-747	44	11	sglt2	sglt2	ADJ
ajcp-747	44	12	inhibitors	inhibitor	NOUN
ajcp-747	44	13	(	(	PUNCT
ajcp-747	44	14	empagliflozin	empagliflozin	PROPN
ajcp-747	44	15	,	,	PUNCT
ajcp-747	44	16	canagliflozin	canagliflozin	NOUN
ajcp-747	44	17	,	,	PUNCT
ajcp-747	44	18	and	and	CCONJ
ajcp-747	44	19	dapagliflozin	dapagliflozin	NOUN
ajcp-747	44	20	)	)	PUNCT
ajcp-747	44	21	increases	increase	VERB
ajcp-747	44	22	the	the	DET
ajcp-747	44	23	likelihood	likelihood	NOUN
ajcp-747	44	24	of	of	ADP
ajcp-747	44	25	euglycemic	euglycemic	PROPN
ajcp-747	44	26	dka	dka	PROPN
ajcp-747	44	27	discrete	discrete	ADJ
ajcp-747	44	28	to	to	ADP
ajcp-747	44	29	the	the	DET
ajcp-747	44	30	length	length	NOUN
ajcp-747	44	31	of	of	ADP
ajcp-747	44	32	treatment	treatment	NOUN
ajcp-747	44	33	(	(	PUNCT
ajcp-747	44	34	peters	peters	PROPN
ajcp-747	44	35	et	et	PROPN
ajcp-747	44	36	al	al	PROPN
ajcp-747	44	37	.	.	PROPN
ajcp-747	44	38	,	,	PUNCT
ajcp-747	44	39	2015	2015	NUM
ajcp-747	44	40	;	;	PUNCT
ajcp-747	44	41	somagutta	somagutta	NOUN
ajcp-747	44	42	et	et	PROPN
ajcp-747	44	43	al	al	PROPN
ajcp-747	44	44	.	.	PROPN
ajcp-747	44	45	,	,	PUNCT
ajcp-747	44	46	2021	2021	NUM
ajcp-747	44	47	;	;	PUNCT
ajcp-747	44	48	taylor	taylor	PROPN
ajcp-747	44	49	et	et	PROPN
ajcp-747	44	50	al	al	PROPN
ajcp-747	44	51	.	.	PROPN
ajcp-747	44	52	,	,	PUNCT
ajcp-747	44	53	2015	2015	NUM
ajcp-747	44	54	)	)	PUNCT
ajcp-747	44	55	.	.	PUNCT
ajcp-747	45	1	however	however	ADV
ajcp-747	45	2	,	,	PUNCT
ajcp-747	45	3	the	the	DET
ajcp-747	45	4	prevalence	prevalence	NOUN
ajcp-747	45	5	of	of	ADP
ajcp-747	45	6	edka	edka	NOUN
ajcp-747	45	7	increased	increase	VERB
ajcp-747	45	8	after	after	ADP
ajcp-747	45	9	the	the	DET
ajcp-747	45	10	introduction	introduction	NOUN
ajcp-747	45	11	of	of	ADP
ajcp-747	45	12	sodiumglucose	sodiumglucose	NOUN
ajcp-747	45	13	transporter	transporter	NOUN
ajcp-747	45	14	2	2	NUM
ajcp-747	45	15	(	(	PUNCT
ajcp-747	45	16	sglt2	sglt2	NOUN
ajcp-747	45	17	)	)	PUNCT
ajcp-747	45	18	inhibitors	inhibitor	NOUN
ajcp-747	45	19	in	in	ADP
ajcp-747	45	20	some	some	DET
ajcp-747	45	21	rare	rare	ADJ
ajcp-747	45	22	cases	case	NOUN
ajcp-747	45	23	.	.	PUNCT
ajcp-747	46	1	although	although	SCONJ
ajcp-747	46	2	there	there	PRON
ajcp-747	46	3	have	have	AUX
ajcp-747	46	4	been	be	AUX
ajcp-747	46	5	few	few	ADJ
ajcp-747	46	6	reports	report	NOUN
ajcp-747	46	7	of	of	ADP
ajcp-747	46	8	dka	dka	NOUN
ajcp-747	46	9	in	in	ADP
ajcp-747	46	10	sglt2i	sglt2i	NOUN
ajcp-747	46	11	investigations	investigation	NOUN
ajcp-747	46	12	,	,	PUNCT
ajcp-747	46	13	the	the	DET
ajcp-747	46	14	precise	precise	ADJ
ajcp-747	46	15	numbers	number	NOUN
ajcp-747	46	16	of	of	ADP
ajcp-747	46	17	edka	edka	ADJ
ajcp-747	46	18	events	event	NOUN
ajcp-747	46	19	have	have	AUX
ajcp-747	46	20	not	not	PART
ajcp-747	46	21	been	be	AUX
ajcp-747	46	22	evaluated	evaluate	VERB
ajcp-747	46	23	(	(	PUNCT
ajcp-747	46	24	wibawa	wibawa	X
ajcp-747	46	25	et	et	NOUN
ajcp-747	46	26	al	al	PROPN
ajcp-747	46	27	.	.	PROPN
ajcp-747	46	28	,	,	PUNCT
ajcp-747	46	29	2021	2021	NUM
ajcp-747	46	30	)	)	PUNCT
ajcp-747	46	31	.	.	PUNCT
ajcp-747	47	1	the	the	DET
ajcp-747	47	2	results	result	NOUN
ajcp-747	47	3	of	of	ADP
ajcp-747	47	4	another	another	DET
ajcp-747	47	5	trial,“the	trial,“the	DET
ajcp-747	47	6	empa	empa	NOUN
ajcp-747	47	7	-	-	PUNCT
ajcp-747	47	8	reg	reg	NOUN
ajcp-747	47	9	outcome	outcome	NOUN
ajcp-747	47	10	(	(	PUNCT
ajcp-747	47	11	empagliflozin	empagliflozin	PROPN
ajcp-747	47	12	cardiovascular	cardiovascular	ADJ
ajcp-747	47	13	outcome	outcome	NOUN
ajcp-747	47	14	event	event	NOUN
ajcp-747	47	15	trial	trial	NOUN
ajcp-747	47	16	in	in	ADP
ajcp-747	47	17	type	type	NOUN
ajcp-747	47	18	2	2	NUM
ajcp-747	47	19	diabetes	diabetes	NOUN
ajcp-747	47	20	mellitus	mellitus	NOUN
ajcp-747	47	21	patients	patient	NOUN
ajcp-747	47	22	-	-	PUNCT
ajcp-747	47	23	removing	remove	VERB
ajcp-747	47	24	excess	excess	ADJ
ajcp-747	47	25	glucose	glucose	NOUN
ajcp-747	47	26	)	)	PUNCT
ajcp-747	47	27	”	"	PUNCT
ajcp-747	47	28	study	study	NOUN
ajcp-747	47	29	,	,	PUNCT
ajcp-747	47	30	revealed	reveal	VERB
ajcp-747	47	31	that	that	SCONJ
ajcp-747	47	32	dka	dka	PROPN
ajcp-747	47	33	occurs	occur	VERB
ajcp-747	47	34	less	less	ADV
ajcp-747	47	35	frequently	frequently	ADV
ajcp-747	47	36	than	than	ADP
ajcp-747	47	37	0.1	0.1	NUM
ajcp-747	47	38	%	%	NOUN
ajcp-747	47	39	of	of	ADP
ajcp-747	47	40	the	the	DET
ajcp-747	47	41	duration	duration	NOUN
ajcp-747	47	42	(	(	PUNCT
ajcp-747	47	43	rosenstock	rosenstock	NOUN
ajcp-747	47	44	,	,	PUNCT
ajcp-747	47	45	2015	2015	NUM
ajcp-747	47	46	;	;	PUNCT
ajcp-747	47	47	sampani	sampani	PROPN
ajcp-747	47	48	et	et	PROPN
ajcp-747	47	49	al	al	PROPN
ajcp-747	47	50	.	.	PROPN
ajcp-747	47	51	,	,	PUNCT
ajcp-747	47	52	2020	2020	NUM
ajcp-747	47	53	)	)	PUNCT
ajcp-747	47	54	.	.	PUNCT
ajcp-747	48	1	rates	rate	NOUN
ajcp-747	48	2	of	of	ADP
ajcp-747	48	3	dka	dka	NOUN
ajcp-747	48	4	-	-	PUNCT
ajcp-747	48	5	related	relate	VERB
ajcp-747	48	6	occurrences	occurrence	NOUN
ajcp-747	48	7	among	among	ADP
ajcp-747	48	8	type	type	NOUN
ajcp-747	48	9	2	2	NUM
ajcp-747	48	10	diabetic	diabetic	ADJ
ajcp-747	48	11	patients	patient	NOUN
ajcp-747	48	12	on	on	ADP
ajcp-747	48	13	sglt2	sglt2	ADJ
ajcp-747	48	14	inhibitors	inhibitor	NOUN
ajcp-747	48	15	ranged	range	VERB
ajcp-747	48	16	from	from	ADP
ajcp-747	48	17	0.16	0.16	NUM
ajcp-747	48	18	to	to	ADP
ajcp-747	48	19	0.76	0.76	NUM
ajcp-747	48	20	events	event	NOUN
ajcp-747	48	21	per	per	ADP
ajcp-747	48	22	1000	1000	NUM
ajcp-747	48	23	patient	patient	NOUN
ajcp-747	48	24	years	year	NOUN
ajcp-747	48	25	(	(	PUNCT
ajcp-747	48	26	goldenberg	goldenberg	PROPN
ajcp-747	48	27	et	et	NOUN
ajcp-747	48	28	al	al	PROPN
ajcp-747	48	29	.	.	PROPN
ajcp-747	48	30	,	,	PUNCT
ajcp-747	48	31	2016).sglt2	2016).sglt2	NUM
ajcp-747	48	32	inhibitors	inhibitor	NOUN
ajcp-747	48	33	raise	raise	VERB
ajcp-747	48	34	the	the	DET
ajcp-747	48	35	risk	risk	NOUN
ajcp-747	48	36	of	of	ADP
ajcp-747	48	37	dka	dka	PROPN
ajcp-747	48	38	in	in	ADP
ajcp-747	48	39	t2d	t2d	NOUN
ajcp-747	48	40	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-747	48	41	pa	pa	PROPN
ajcp-747	48	42	ge	ge	PROPN
ajcp-747	48	43	3	3	NUM
ajcp-747	48	44	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-747	48	45	am	be	AUX
ajcp-747	48	46	.	.	PUNCT
ajcp-747	49	1	j.	j.	PROPN
ajcp-747	49	2	chem	chem	PROPN
ajcp-747	49	3	.	.	PUNCT
ajcp-747	50	1	pharm	pharm	PROPN
ajcp-747	50	2	.	.	PUNCT
ajcp-747	51	1	1(2	1(2	NUM
ajcp-747	51	2	)	)	PUNCT
ajcp-747	51	3	1	1	NUM
ajcp-747	51	4	-	-	SYM
ajcp-747	51	5	4	4	NUM
ajcp-747	51	6	,	,	PUNCT
ajcp-747	51	7	2022	2022	NUM
ajcp-747	51	8	patients	patient	NOUN
ajcp-747	51	9	by	by	ADP
ajcp-747	51	10	seven	seven	NUM
ajcp-747	51	11	times	time	NOUN
ajcp-747	51	12	(	(	PUNCT
ajcp-747	51	13	blau	blau	PROPN
ajcp-747	51	14	et	et	PROPN
ajcp-747	51	15	al	al	PROPN
ajcp-747	51	16	.	.	PROPN
ajcp-747	51	17	,	,	PUNCT
ajcp-747	51	18	2017	2017	NUM
ajcp-747	51	19	)	)	PUNCT
ajcp-747	51	20	.	.	PUNCT
ajcp-747	52	1	according	accord	VERB
ajcp-747	52	2	to	to	ADP
ajcp-747	52	3	other	other	ADJ
ajcp-747	52	4	studies	study	NOUN
ajcp-747	52	5	,	,	PUNCT
ajcp-747	52	6	sglt2i	sglt2i	PROPN
ajcp-747	52	7	improves	improve	VERB
ajcp-747	52	8	beta	beta	ADJ
ajcp-747	52	9	cells	cell	NOUN
ajcp-747	52	10	in	in	ADP
ajcp-747	52	11	the	the	DET
ajcp-747	52	12	pancreas	pancreas	NOUN
ajcp-747	52	13	,	,	PUNCT
ajcp-747	52	14	increasing	increase	VERB
ajcp-747	52	15	lipolysis	lipolysis	NOUN
ajcp-747	52	16	and	and	CCONJ
ajcp-747	52	17	raising	raise	VERB
ajcp-747	52	18	the	the	DET
ajcp-747	52	19	concentration	concentration	NOUN
ajcp-747	52	20	of	of	ADP
ajcp-747	52	21	ketone	ketone	NOUN
ajcp-747	52	22	bodies	body	NOUN
ajcp-747	52	23	(	(	PUNCT
ajcp-747	52	24	da	da	PROPN
ajcp-747	52	25	silva	silva	PROPN
ajcp-747	52	26	et	et	PROPN
ajcp-747	52	27	al	al	PROPN
ajcp-747	52	28	.	.	PROPN
ajcp-747	52	29	,	,	PUNCT
ajcp-747	52	30	2018	2018	NUM
ajcp-747	52	31	)	)	PUNCT
ajcp-747	52	32	.	.	PUNCT
ajcp-747	53	1	they	they	PRON
ajcp-747	53	2	have	have	AUX
ajcp-747	53	3	also	also	ADV
ajcp-747	53	4	been	be	AUX
ajcp-747	53	5	indicated	indicate	VERB
ajcp-747	53	6	to	to	PART
ajcp-747	53	7	activate	activate	VERB
ajcp-747	53	8	the	the	DET
ajcp-747	53	9	pancreatic	pancreatic	ADJ
ajcp-747	53	10	alpha	alpha	NOUN
ajcp-747	53	11	cells	cell	NOUN
ajcp-747	53	12	,	,	PUNCT
ajcp-747	53	13	triggering	trigger	VERB
ajcp-747	53	14	glucagon	glucagon	NOUN
ajcp-747	53	15	production	production	NOUN
ajcp-747	53	16	and	and	CCONJ
ajcp-747	53	17	inducing	induce	VERB
ajcp-747	53	18	an	an	DET
ajcp-747	53	19	imbalance	imbalance	NOUN
ajcp-747	53	20	in	in	ADP
ajcp-747	53	21	insulin	insulin	NOUN
ajcp-747	53	22	and	and	CCONJ
ajcp-747	53	23	glucagon	glucagon	NOUN
ajcp-747	53	24	level	level	NOUN
ajcp-747	53	25	(	(	PUNCT
ajcp-747	53	26	candelario	candelario	NOUN
ajcp-747	53	27	&	&	CCONJ
ajcp-747	53	28	wykretowicz	wykretowicz	PROPN
ajcp-747	53	29	,	,	PUNCT
ajcp-747	53	30	2016	2016	NUM
ajcp-747	53	31	;	;	PUNCT
ajcp-747	53	32	pfützner	pfützn	ADJ
ajcp-747	53	33	et	et	PROPN
ajcp-747	53	34	al	al	PROPN
ajcp-747	53	35	.	.	PROPN
ajcp-747	53	36	,	,	PUNCT
ajcp-747	53	37	2017	2017	NUM
ajcp-747	53	38	)	)	PUNCT
ajcp-747	53	39	.	.	PUNCT
ajcp-747	54	1	the	the	DET
ajcp-747	54	2	patient	patient	NOUN
ajcp-747	54	3	,	,	PUNCT
ajcp-747	54	4	in	in	ADP
ajcp-747	54	5	this	this	DET
ajcp-747	54	6	case	case	NOUN
ajcp-747	54	7	,	,	PUNCT
ajcp-747	54	8	presented	present	VERB
ajcp-747	54	9	with	with	ADP
ajcp-747	54	10	acute	acute	PROPN
ajcp-747	54	11	pancreatitis	pancreatitis	PROPN
ajcp-747	54	12	while	while	SCONJ
ajcp-747	54	13	taking	take	VERB
ajcp-747	54	14	prescribed	prescribed	ADJ
ajcp-747	54	15	empagliflozin	empagliflozin	NOUN
ajcp-747	54	16	,	,	PUNCT
ajcp-747	54	17	and	and	CCONJ
ajcp-747	54	18	there	there	PRON
ajcp-747	54	19	was	be	VERB
ajcp-747	54	20	no	no	DET
ajcp-747	54	21	known	known	ADJ
ajcp-747	54	22	cause	cause	NOUN
ajcp-747	54	23	of	of	ADP
ajcp-747	54	24	pancreatitis	pancreatitis	NOUN
ajcp-747	54	25	,	,	PUNCT
ajcp-747	54	26	such	such	ADJ
ajcp-747	54	27	as	as	ADP
ajcp-747	54	28	gallstones	gallstone	NOUN
ajcp-747	54	29	or	or	CCONJ
ajcp-747	54	30	alcohol	alcohol	NOUN
ajcp-747	54	31	consumption	consumption	NOUN
ajcp-747	54	32	.	.	PUNCT
ajcp-747	55	1	the	the	DET
ajcp-747	55	2	development	development	NOUN
ajcp-747	55	3	of	of	ADP
ajcp-747	55	4	pancreatitis	pancreatitis	PROPN
ajcp-747	55	5	with	with	ADP
ajcp-747	55	6	regular	regular	ADJ
ajcp-747	55	7	exposure	exposure	NOUN
ajcp-747	55	8	to	to	ADP
ajcp-747	55	9	the	the	DET
ajcp-747	55	10	medication	medication	NOUN
ajcp-747	55	11	and	and	CCONJ
ajcp-747	55	12	the	the	DET
ajcp-747	55	13	symptom	symptom	NOUN
ajcp-747	55	14	treatment	treatment	NOUN
ajcp-747	55	15	response	response	NOUN
ajcp-747	55	16	after	after	SCONJ
ajcp-747	55	17	withdrawal	withdrawal	NOUN
ajcp-747	55	18	make	make	VERB
ajcp-747	55	19	empagliflozin	empagliflozin	NOUN
ajcp-747	55	20	a	a	DET
ajcp-747	55	21	plausible	plausible	ADJ
ajcp-747	55	22	cause	cause	NOUN
ajcp-747	55	23	of	of	ADP
ajcp-747	55	24	pancreatitis	pancreatitis	NOUN
ajcp-747	55	25	.	.	PUNCT
ajcp-747	56	1	the	the	DET
ajcp-747	56	2	molecular	molecular	ADJ
ajcp-747	56	3	basis	basis	NOUN
ajcp-747	56	4	of	of	ADP
ajcp-747	56	5	pancreatitis	pancreatitis	PROPN
ajcp-747	56	6	caused	cause	VERB
ajcp-747	56	7	by	by	ADP
ajcp-747	56	8	empagliflozin	empagliflozin	PROPN
ajcp-747	56	9	is	be	AUX
ajcp-747	56	10	unidentified	unidentified	ADJ
ajcp-747	56	11	.	.	PUNCT
ajcp-747	57	1	it	it	PRON
ajcp-747	57	2	is	be	AUX
ajcp-747	57	3	an	an	DET
ajcp-747	57	4	unusual	unusual	ADJ
ajcp-747	57	5	reaction	reaction	NOUN
ajcp-747	57	6	similar	similar	ADJ
ajcp-747	57	7	to	to	ADP
ajcp-747	57	8	previous	previous	ADJ
ajcp-747	57	9	cases	case	NOUN
ajcp-747	57	10	of	of	ADP
ajcp-747	57	11	druginduced	druginduced	ADJ
ajcp-747	57	12	pancreatitis	pancreatitis	PROPN
ajcp-747	57	13	because	because	SCONJ
ajcp-747	57	14	of	of	ADP
ajcp-747	57	15	the	the	DET
ajcp-747	57	16	immunologic	immunologic	ADJ
ajcp-747	57	17	or	or	CCONJ
ajcp-747	57	18	cytotoxicity	cytotoxicity	NOUN
ajcp-747	57	19	effects	effect	NOUN
ajcp-747	57	20	the	the	DET
ajcp-747	57	21	drug	drug	NOUN
ajcp-747	57	22	or	or	CCONJ
ajcp-747	57	23	its	its	PRON
ajcp-747	57	24	metabolites	metabolite	NOUN
ajcp-747	57	25	have	have	VERB
ajcp-747	57	26	on	on	ADP
ajcp-747	57	27	the	the	DET
ajcp-747	57	28	body	body	NOUN
ajcp-747	57	29	.	.	PUNCT
ajcp-747	58	1	conclusion	conclusion	NOUN
ajcp-747	58	2	the	the	DET
ajcp-747	58	3	fda	fda	PROPN
ajcp-747	58	4	’s	’s	PART
ajcp-747	58	5	warning	warning	NOUN
ajcp-747	58	6	is	be	AUX
ajcp-747	58	7	supported	support	VERB
ajcp-747	58	8	by	by	ADP
ajcp-747	58	9	multiple	multiple	ADJ
ajcp-747	58	10	pieces	piece	NOUN
ajcp-747	58	11	of	of	ADP
ajcp-747	58	12	literature	literature	NOUN
ajcp-747	58	13	that	that	PRON
ajcp-747	58	14	detail	detail	VERB
ajcp-747	58	15	many	many	ADJ
ajcp-747	58	16	physiologically	physiologically	ADV
ajcp-747	58	17	tenable	tenable	ADJ
ajcp-747	58	18	possibilities	possibility	NOUN
ajcp-747	58	19	for	for	ADP
ajcp-747	58	20	negative	negative	ADJ
ajcp-747	58	21	consequences	consequence	NOUN
ajcp-747	58	22	of	of	ADP
ajcp-747	58	23	sglt2	sglt2	X
ajcp-747	58	24	(	(	PUNCT
ajcp-747	58	25	empagliflozin	empagliflozin	PROPN
ajcp-747	58	26	)	)	PUNCT
ajcp-747	58	27	inhibitor	inhibitor	NOUN
ajcp-747	58	28	.	.	PUNCT
ajcp-747	59	1	the	the	DET
ajcp-747	59	2	preponderance	preponderance	NOUN
ajcp-747	59	3	of	of	ADP
ajcp-747	59	4	the	the	DET
ajcp-747	59	5	data	datum	NOUN
ajcp-747	59	6	supports	support	VERB
ajcp-747	59	7	the	the	DET
ajcp-747	59	8	causative	causative	ADJ
ajcp-747	59	9	involvement	involvement	NOUN
ajcp-747	59	10	of	of	ADP
ajcp-747	59	11	sglt2	sglt2	ADJ
ajcp-747	59	12	inhibitors	inhibitor	NOUN
ajcp-747	59	13	in	in	ADP
ajcp-747	59	14	the	the	DET
ajcp-747	59	15	pathogenesis	pathogenesis	NOUN
ajcp-747	59	16	of	of	ADP
ajcp-747	59	17	acute	acute	PROPN
ajcp-747	59	18	pancreatitis	pancreatitis	PROPN
ajcp-747	59	19	and	and	CCONJ
ajcp-747	59	20	edka	edka	NOUN
ajcp-747	59	21	.	.	PUNCT
ajcp-747	60	1	therefore	therefore	ADV
ajcp-747	60	2	,	,	PUNCT
ajcp-747	60	3	sglt-2	sglt-2	NUM
ajcp-747	60	4	inhibitor	inhibitor	NOUN
ajcp-747	60	5	initiation	initiation	NOUN
ajcp-747	60	6	should	should	AUX
ajcp-747	60	7	be	be	AUX
ajcp-747	60	8	avoided	avoid	VERB
ajcp-747	60	9	in	in	ADP
ajcp-747	60	10	acute	acute	ADJ
ajcp-747	60	11	conditions	condition	NOUN
ajcp-747	60	12	.	.	PUNCT
ajcp-747	61	1	since	since	SCONJ
ajcp-747	61	2	normoglycemia	normoglycemia	NOUN
ajcp-747	61	3	might	might	AUX
ajcp-747	61	4	mask	mask	VERB
ajcp-747	61	5	the	the	DET
ajcp-747	61	6	presence	presence	NOUN
ajcp-747	61	7	of	of	ADP
ajcp-747	61	8	acidosis	acidosis	NOUN
ajcp-747	61	9	,	,	PUNCT
ajcp-747	61	10	medical	medical	ADJ
ajcp-747	61	11	professionals	professional	NOUN
ajcp-747	61	12	should	should	AUX
ajcp-747	61	13	be	be	AUX
ajcp-747	61	14	aware	aware	ADJ
ajcp-747	61	15	of	of	ADP
ajcp-747	61	16	this	this	DET
ajcp-747	61	17	diagnosis	diagnosis	NOUN
ajcp-747	61	18	and	and	CCONJ
ajcp-747	61	19	immediately	immediately	ADV
ajcp-747	61	20	begin	begin	VERB
ajcp-747	61	21	therapy	therapy	NOUN
ajcp-747	61	22	.	.	PUNCT
ajcp-747	62	1	given	give	VERB
ajcp-747	62	2	the	the	DET
ajcp-747	62	3	nature	nature	NOUN
ajcp-747	62	4	of	of	ADP
ajcp-747	62	5	the	the	DET
ajcp-747	62	6	disease	disease	NOUN
ajcp-747	62	7	,	,	PUNCT
ajcp-747	62	8	edka	edka	PROPN
ajcp-747	62	9	should	should	AUX
ajcp-747	62	10	be	be	AUX
ajcp-747	62	11	retained	retain	VERB
ajcp-747	62	12	in	in	ADP
ajcp-747	62	13	the	the	DET
ajcp-747	62	14	differential	differential	NOUN
ajcp-747	62	15	even	even	ADV
ajcp-747	62	16	if	if	SCONJ
ajcp-747	62	17	it	it	PRON
ajcp-747	62	18	is	be	AUX
ajcp-747	62	19	rare	rare	ADJ
ajcp-747	62	20	.	.	PUNCT
ajcp-747	63	1	patients	patient	NOUN
ajcp-747	63	2	should	should	AUX
ajcp-747	63	3	be	be	AUX
ajcp-747	63	4	informed	inform	VERB
ajcp-747	63	5	about	about	ADP
ajcp-747	63	6	negative	negative	ADJ
ajcp-747	63	7	consequences	consequence	NOUN
ajcp-747	63	8	and	and	CCONJ
ajcp-747	63	9	stimuli	stimuli	VERB
ajcp-747	63	10	to	to	PART
ajcp-747	63	11	prevent	prevent	VERB
ajcp-747	63	12	recurrences	recurrence	NOUN
ajcp-747	63	13	.	.	PUNCT
ajcp-747	64	1	acknowledgement	acknowledgement	NOUN
ajcp-747	64	2	the	the	DET
ajcp-747	64	3	authors	author	NOUN
ajcp-747	64	4	are	be	AUX
ajcp-747	64	5	grateful	grateful	ADJ
ajcp-747	64	6	to	to	ADP
ajcp-747	64	7	the	the	DET
ajcp-747	64	8	mediclinic	mediclinic	PROPN
ajcp-747	64	9	al	al	PROPN
ajcp-747	64	10	jowhara	jowhara	PROPN
ajcp-747	64	11	hospital	hospital	PROPN
ajcp-747	64	12	for	for	ADP
ajcp-747	64	13	their	their	PRON
ajcp-747	64	14	consistent	consistent	ADJ
ajcp-747	64	15	support	support	NOUN
ajcp-747	64	16	throughout	throughout	ADP
ajcp-747	64	17	the	the	DET
ajcp-747	64	18	research	research	NOUN
ajcp-747	64	19	.	.	PUNCT
ajcp-747	65	1	references	reference	NOUN
ajcp-747	65	2	blau	blau	PROPN
ajcp-747	65	3	,	,	PUNCT
ajcp-747	65	4	j.	j.	PROPN
ajcp-747	65	5	e.	e.	PROPN
ajcp-747	65	6	,	,	PUNCT
ajcp-747	65	7	tella	tella	PROPN
ajcp-747	65	8	,	,	PUNCT
ajcp-747	65	9	s.	s.	PROPN
ajcp-747	65	10	h.	h.	PROPN
ajcp-747	65	11	,	,	PUNCT
ajcp-747	65	12	taylor	taylor	PROPN
ajcp-747	65	13	,	,	PUNCT
ajcp-747	65	14	s.	s.	PROPN
ajcp-747	65	15	i.	i.	PROPN
ajcp-747	65	16	,	,	PUNCT
ajcp-747	65	17	&	&	CCONJ
ajcp-747	65	18	rother	rother	PROPN
ajcp-747	65	19	,	,	PUNCT
ajcp-747	65	20	k.	k.	PROPN
ajcp-747	65	21	i.	i.	PROPN
ajcp-747	65	22	(	(	PUNCT
ajcp-747	65	23	2017	2017	NUM
ajcp-747	65	24	)	)	PUNCT
ajcp-747	65	25	.	.	PUNCT
ajcp-747	66	1	ketoacidosis	ketoacidosis	NOUN
ajcp-747	66	2	associated	associate	VERB
ajcp-747	66	3	with	with	ADP
ajcp-747	66	4	sglt2	sglt2	ADJ
ajcp-747	66	5	inhibitor	inhibitor	NOUN
ajcp-747	66	6	treatment	treatment	NOUN
ajcp-747	66	7	:	:	PUNCT
ajcp-747	66	8	analysis	analysis	NOUN
ajcp-747	66	9	of	of	ADP
ajcp-747	66	10	faers	faer	NOUN
ajcp-747	66	11	data	datum	NOUN
ajcp-747	66	12	.	.	PUNCT
ajcp-747	67	1	diabetes	diabetes	NOUN
ajcp-747	67	2	/	/	SYM
ajcp-747	67	3	metabolism	metabolism	NOUN
ajcp-747	67	4	research	research	NOUN
ajcp-747	67	5	and	and	CCONJ
ajcp-747	67	6	reviews	review	NOUN
ajcp-747	67	7	,	,	PUNCT
ajcp-747	67	8	33(8	33(8	NUM
ajcp-747	67	9	)	)	PUNCT
ajcp-747	67	10	,	,	PUNCT
ajcp-747	67	11	e2924	e2924	NOUN
ajcp-747	67	12	.	.	PUNCT
ajcp-747	68	1	calçada	calçada	PROPN
ajcp-747	68	2	,	,	PUNCT
ajcp-747	68	3	m.	m.	PROPN
ajcp-747	68	4	b.	b.	PROPN
ajcp-747	68	5	,	,	PUNCT
ajcp-747	68	6	fernandes	fernandes	PROPN
ajcp-747	68	7	,	,	PUNCT
ajcp-747	68	8	l.	l.	PROPN
ajcp-747	68	9	,	,	PUNCT
ajcp-747	68	10	soares	soares	PROPN
ajcp-747	68	11	costa	costa	PROPN
ajcp-747	68	12	,	,	PUNCT
ajcp-747	68	13	r.	r.	PROPN
ajcp-747	68	14	,	,	PUNCT
ajcp-747	68	15	montezinho	montezinho	PROPN
ajcp-747	68	16	,	,	PUNCT
ajcp-747	68	17	s.	s.	PROPN
ajcp-747	68	18	,	,	PUNCT
ajcp-747	68	19	martins	martins	PROPN
ajcp-747	68	20	duarte	duarte	PROPN
ajcp-747	68	21	,	,	PUNCT
ajcp-747	68	22	f.	f.	PROPN
ajcp-747	68	23	,	,	PUNCT
ajcp-747	68	24	frutuoso	frutuoso	NOUN
ajcp-747	68	25	,	,	PUNCT
ajcp-747	68	26	l.	l.	PROPN
ajcp-747	68	27	,	,	PUNCT
ajcp-747	68	28	&	&	CCONJ
ajcp-747	68	29	freitas	freitas	PROPN
ajcp-747	68	30	,	,	PUNCT
ajcp-747	68	31	a.	a.	PROPN
ajcp-747	68	32	r.	r.	PROPN
ajcp-747	68	33	(	(	PUNCT
ajcp-747	68	34	2021	2021	NUM
ajcp-747	68	35	)	)	PUNCT
ajcp-747	68	36	.	.	PUNCT
ajcp-747	69	1	euglycemic	euglycemic	ADJ
ajcp-747	69	2	diabetic	diabetic	ADJ
ajcp-747	69	3	ketoacidosis	ketoacidosis	NOUN
ajcp-747	69	4	after	after	ADP
ajcp-747	69	5	a	a	DET
ajcp-747	69	6	single	single	ADJ
ajcp-747	69	7	dose	dose	NOUN
ajcp-747	69	8	of	of	ADP
ajcp-747	69	9	empagliflozin	empagliflozin	PROPN
ajcp-747	69	10	in	in	ADP
ajcp-747	69	11	a	a	DET
ajcp-747	69	12	patient	patient	NOUN
ajcp-747	69	13	with	with	ADP
ajcp-747	69	14	pancreatitis	pancreatitis	PROPN
ajcp-747	69	15	.	.	PUNCT
ajcp-747	70	1	clinics	clinic	NOUN
ajcp-747	70	2	and	and	CCONJ
ajcp-747	70	3	practice	practice	NOUN
ajcp-747	70	4	,	,	PUNCT
ajcp-747	70	5	11(2	11(2	NOUN
ajcp-747	70	6	)	)	PUNCT
ajcp-747	70	7	,	,	PUNCT
ajcp-747	70	8	216	216	NUM
ajcp-747	70	9	-	-	SYM
ajcp-747	70	10	218	218	NUM
ajcp-747	70	11	.	.	PUNCT
ajcp-747	71	1	candelario	candelario	NOUN
ajcp-747	71	2	,	,	PUNCT
ajcp-747	71	3	n.	n.	NOUN
ajcp-747	71	4	,	,	PUNCT
ajcp-747	71	5	&	&	CCONJ
ajcp-747	71	6	wykretowicz	wykretowicz	PROPN
ajcp-747	71	7	,	,	PUNCT
ajcp-747	71	8	j.	j.	PROPN
ajcp-747	71	9	(	(	PUNCT
ajcp-747	71	10	2016	2016	NUM
ajcp-747	71	11	)	)	PUNCT
ajcp-747	71	12	.	.	PUNCT
ajcp-747	72	1	the	the	DET
ajcp-747	72	2	dka	dka	PROPN
ajcp-747	72	3	that	that	PRON
ajcp-747	72	4	was	be	AUX
ajcp-747	72	5	n’t	n’t	ADJ
ajcp-747	72	6	:	:	PUNCT
ajcp-747	72	7	a	a	DET
ajcp-747	72	8	case	case	NOUN
ajcp-747	72	9	of	of	ADP
ajcp-747	72	10	euglycemic	euglycemic	ADJ
ajcp-747	72	11	diabetic	diabetic	ADJ
ajcp-747	72	12	ketoacidosis	ketoacidosis	NOUN
ajcp-747	72	13	due	due	ADP
ajcp-747	72	14	to	to	ADP
ajcp-747	72	15	empagliflozin	empagliflozin	PROPN
ajcp-747	72	16	.	.	PUNCT
ajcp-747	73	1	oxford	oxford	PROPN
ajcp-747	73	2	medical	medical	ADJ
ajcp-747	73	3	case	case	NOUN
ajcp-747	73	4	reports	report	VERB
ajcp-747	73	5	,	,	PUNCT
ajcp-747	73	6	7	7	NUM
ajcp-747	73	7	,	,	PUNCT
ajcp-747	73	8	144	144	NUM
ajcp-747	73	9	-	-	SYM
ajcp-747	73	10	146	146	NUM
ajcp-747	73	11	.	.	PUNCT
ajcp-747	74	1	da	da	PROPN
ajcp-747	74	2	silva	silva	PROPN
ajcp-747	74	3	,	,	PUNCT
ajcp-747	74	4	p.	p.	PROPN
ajcp-747	74	5	n.	n.	PROPN
ajcp-747	74	6	,	,	PUNCT
ajcp-747	74	7	da	da	PROPN
ajcp-747	74	8	conceição	conceição	PROPN
ajcp-747	74	9	,	,	PUNCT
ajcp-747	74	10	r.	r.	PROPN
ajcp-747	74	11	a.	a.	PROPN
ajcp-747	74	12	,	,	PUNCT
ajcp-747	74	13	do	do	VERB
ajcp-747	74	14	couto	couto	PROPN
ajcp-747	74	15	maia	maia	PROPN
ajcp-747	74	16	,	,	PUNCT
ajcp-747	74	17	r.	r.	PROPN
ajcp-747	74	18	,	,	PUNCT
ajcp-747	74	19	&	&	CCONJ
ajcp-747	74	20	de	de	PROPN
ajcp-747	74	21	castro	castro	PROPN
ajcp-747	74	22	barbosa	barbosa	PROPN
ajcp-747	74	23	,	,	PUNCT
ajcp-747	74	24	m.	m.	NOUN
ajcp-747	74	25	l.	l.	PROPN
ajcp-747	74	26	(	(	PUNCT
ajcp-747	74	27	2018	2018	NUM
ajcp-747	74	28	)	)	PUNCT
ajcp-747	74	29	.	.	PUNCT
ajcp-747	75	1	sodium	sodium	NOUN
ajcp-747	75	2	–	–	PUNCT
ajcp-747	75	3	glucose	glucose	NOUN
ajcp-747	75	4	cotransporter	cotransporter	NOUN
ajcp-747	75	5	2	2	NUM
ajcp-747	75	6	(	(	PUNCT
ajcp-747	75	7	sglt-2	sglt-2	NOUN
ajcp-747	75	8	)	)	PUNCT
ajcp-747	75	9	inhibitors	inhibitor	NOUN
ajcp-747	75	10	:	:	PUNCT
ajcp-747	75	11	a	a	DET
ajcp-747	75	12	new	new	ADJ
ajcp-747	75	13	antidiabetic	antidiabetic	ADJ
ajcp-747	75	14	drug	drug	NOUN
ajcp-747	75	15	class	class	NOUN
ajcp-747	75	16	.	.	PUNCT
ajcp-747	76	1	medchemcomm	medchemcomm	NOUN
ajcp-747	76	2	,	,	PUNCT
ajcp-747	76	3	9(8	9(8	NUM
ajcp-747	76	4	)	)	PUNCT
ajcp-747	76	5	,	,	PUNCT
ajcp-747	76	6	1273	1273	NUM
ajcp-747	76	7	-	-	SYM
ajcp-747	76	8	1281	1281	NUM
ajcp-747	76	9	.	.	PUNCT
ajcp-747	77	1	do	do	VERB
ajcp-747	77	2	,	,	PUNCT
ajcp-747	77	3	w.	w.	PROPN
ajcp-747	77	4	y.	y.	PROPN
ajcp-747	77	5	c.	c.	PROPN
ajcp-747	77	6	(	(	PUNCT
ajcp-747	77	7	n.d	n.d	PROPN
ajcp-747	77	8	.	.	PROPN
ajcp-747	77	9	)	)	PUNCT
ajcp-747	77	10	.	.	PUNCT
ajcp-747	78	1	fda	fda	PROPN
ajcp-747	78	2	issues	issue	VERB
ajcp-747	78	3	multiple	multiple	ADJ
ajcp-747	78	4	warnings	warning	NOUN
ajcp-747	78	5	for	for	ADP
ajcp-747	78	6	newest	new	ADJ
ajcp-747	78	7	class	class	NOUN
ajcp-747	78	8	of	of	ADP
ajcp-747	78	9	diabetes	diabetes	NOUN
ajcp-747	78	10	drugs	drug	NOUN
ajcp-747	78	11	.	.	PUNCT
ajcp-747	79	1	goldenberg	goldenberg	PROPN
ajcp-747	79	2	,	,	PUNCT
ajcp-747	79	3	r.	r.	PROPN
ajcp-747	79	4	m.	m.	PROPN
ajcp-747	79	5	,	,	PUNCT
ajcp-747	79	6	berard	berard	PROPN
ajcp-747	79	7	,	,	PUNCT
ajcp-747	79	8	l.	l.	PROPN
ajcp-747	79	9	d.	d.	PROPN
ajcp-747	79	10	,	,	PUNCT
ajcp-747	79	11	cheng	cheng	PROPN
ajcp-747	79	12	,	,	PUNCT
ajcp-747	79	13	a.	a.	PROPN
ajcp-747	79	14	y.	y.	PROPN
ajcp-747	79	15	,	,	PUNCT
ajcp-747	79	16	gilbert	gilbert	PROPN
ajcp-747	79	17	,	,	PUNCT
ajcp-747	79	18	j.	j.	PROPN
ajcp-747	79	19	d.	d.	PROPN
ajcp-747	79	20	,	,	PUNCT
ajcp-747	79	21	verma	verma	PROPN
ajcp-747	79	22	,	,	PUNCT
ajcp-747	79	23	s.	s.	PROPN
ajcp-747	79	24	,	,	PUNCT
ajcp-747	79	25	woo	woo	PROPN
ajcp-747	79	26	,	,	PUNCT
ajcp-747	79	27	v.	v.	PROPN
ajcp-747	79	28	c.	c.	PROPN
ajcp-747	79	29	,	,	PUNCT
ajcp-747	79	30	&	&	CCONJ
ajcp-747	79	31	yale	yale	PROPN
ajcp-747	79	32	,	,	PUNCT
ajcp-747	79	33	j.-f	j.-f	PROPN
ajcp-747	79	34	.	.	PUNCT
ajcp-747	80	1	(	(	PUNCT
ajcp-747	80	2	2016	2016	NUM
ajcp-747	80	3	)	)	PUNCT
ajcp-747	80	4	.	.	PUNCT
ajcp-747	81	1	sglt2	sglt2	PROPN
ajcp-747	81	2	inhibitor	inhibitor	NOUN
ajcp-747	81	3	–	–	PUNCT
ajcp-747	81	4	associated	associate	VERB
ajcp-747	81	5	diabetic	diabetic	ADJ
ajcp-747	81	6	ketoacidosis	ketoacidosis	NOUN
ajcp-747	81	7	:	:	PUNCT
ajcp-747	81	8	clinical	clinical	ADJ
ajcp-747	81	9	review	review	NOUN
ajcp-747	81	10	and	and	CCONJ
ajcp-747	81	11	recommendations	recommendation	NOUN
ajcp-747	81	12	for	for	ADP
ajcp-747	81	13	prevention	prevention	NOUN
ajcp-747	81	14	and	and	CCONJ
ajcp-747	81	15	diagnosis	diagnosis	NOUN
ajcp-747	81	16	.	.	PUNCT
ajcp-747	82	1	clinical	clinical	ADJ
ajcp-747	82	2	therapeutics	therapeutic	NOUN
ajcp-747	82	3	,	,	PUNCT
ajcp-747	82	4	38(12	38(12	NUM
ajcp-747	82	5	)	)	PUNCT
ajcp-747	82	6	,	,	PUNCT
ajcp-747	82	7	2654	2654	NUM
ajcp-747	82	8	-	-	SYM
ajcp-747	82	9	2664	2664	NUM
ajcp-747	82	10	.	.	PUNCT
ajcp-747	83	1	e2651	e2651	PROPN
ajcp-747	83	2	.	.	PUNCT
ajcp-747	84	1	jensen	jensen	PROPN
ajcp-747	84	2	,	,	PUNCT
ajcp-747	84	3	m.	m.	PROPN
ajcp-747	84	4	l.	l.	PROPN
ajcp-747	84	5	,	,	PUNCT
ajcp-747	84	6	persson	persson	PROPN
ajcp-747	84	7	,	,	PUNCT
ajcp-747	84	8	f.	f.	PROPN
ajcp-747	84	9	,	,	PUNCT
ajcp-747	84	10	andersen	andersen	PROPN
ajcp-747	84	11	,	,	PUNCT
ajcp-747	84	12	g.	g.	PROPN
ajcp-747	84	13	s.	s.	PROPN
ajcp-747	84	14	,	,	PUNCT
ajcp-747	84	15	ridderstråle	ridderstråle	NOUN
ajcp-747	84	16	,	,	PUNCT
ajcp-747	84	17	m.	m.	NOUN
ajcp-747	84	18	,	,	PUNCT
ajcp-747	84	19	nolan	nolan	PROPN
ajcp-747	84	20	,	,	PUNCT
ajcp-747	84	21	j.	j.	PROPN
ajcp-747	84	22	j.	j.	PROPN
ajcp-747	84	23	,	,	PUNCT
ajcp-747	84	24	carstensen	carstensen	PROPN
ajcp-747	84	25	,	,	PUNCT
ajcp-747	84	26	b.	b.	PROPN
ajcp-747	84	27	,	,	PUNCT
ajcp-747	84	28	&	&	CCONJ
ajcp-747	84	29	jørgensen	jørgensen	PROPN
ajcp-747	84	30	,	,	PUNCT
ajcp-747	84	31	m.	m.	PROPN
ajcp-747	84	32	e.	e.	PROPN
ajcp-747	84	33	(	(	PUNCT
ajcp-747	84	34	2017	2017	NUM
ajcp-747	84	35	)	)	PUNCT
ajcp-747	84	36	.	.	PUNCT
ajcp-747	85	1	incidence	incidence	NOUN
ajcp-747	85	2	of	of	ADP
ajcp-747	85	3	ketoacidosis	ketoacidosis	NOUN
ajcp-747	85	4	in	in	ADP
ajcp-747	85	5	the	the	DET
ajcp-747	85	6	danish	danish	ADJ
ajcp-747	85	7	type	type	NOUN
ajcp-747	85	8	2	2	NUM
ajcp-747	85	9	diabetes	diabetes	NOUN
ajcp-747	85	10	population	population	NOUN
ajcp-747	85	11	before	before	ADP
ajcp-747	85	12	and	and	CCONJ
ajcp-747	85	13	after	after	ADP
ajcp-747	85	14	introduction	introduction	NOUN
ajcp-747	85	15	of	of	ADP
ajcp-747	85	16	sodium	sodium	NOUN
ajcp-747	85	17	–	–	PUNCT
ajcp-747	85	18	glucose	glucose	NOUN
ajcp-747	85	19	cotransporter	cotransporter	NOUN
ajcp-747	85	20	2	2	NUM
ajcp-747	85	21	inhibitors	inhibitor	NOUN
ajcp-747	85	22	—	—	PUNCT
ajcp-747	85	23	a	a	DET
ajcp-747	85	24	nationwide	nationwide	ADJ
ajcp-747	85	25	,	,	PUNCT
ajcp-747	85	26	retrospective	retrospective	ADJ
ajcp-747	85	27	cohort	cohort	NOUN
ajcp-747	85	28	study	study	NOUN
ajcp-747	85	29	,	,	PUNCT
ajcp-747	85	30	1995–2014	1995–2014	NUM
ajcp-747	85	31	.	.	PUNCT
ajcp-747	86	1	diabetes	diabetes	NOUN
ajcp-747	86	2	care	care	PROPN
ajcp-747	86	3	,	,	PUNCT
ajcp-747	86	4	40(5	40(5	NOUN
ajcp-747	86	5	)	)	PUNCT
ajcp-747	86	6	,	,	PUNCT
ajcp-747	86	7	e57	e57	NOUN
ajcp-747	86	8	-	-	PUNCT
ajcp-747	86	9	e58	e58	NOUN
ajcp-747	86	10	.	.	PUNCT
ajcp-747	87	1	kitabchi	kitabchi	PROPN
ajcp-747	87	2	,	,	PUNCT
ajcp-747	87	3	a.	a.	PROPN
ajcp-747	87	4	e.	e.	PROPN
ajcp-747	87	5	,	,	PUNCT
ajcp-747	87	6	umpierrez	umpierrez	PROPN
ajcp-747	87	7	,	,	PUNCT
ajcp-747	87	8	g.	g.	PROPN
ajcp-747	87	9	e.	e.	PROPN
ajcp-747	87	10	,	,	PUNCT
ajcp-747	87	11	miles	miles	PROPN
ajcp-747	87	12	,	,	PUNCT
ajcp-747	87	13	j.	j.	PROPN
ajcp-747	87	14	m.	m.	PROPN
ajcp-747	87	15	,	,	PUNCT
ajcp-747	87	16	&	&	CCONJ
ajcp-747	87	17	fisher	fisher	PROPN
ajcp-747	87	18	,	,	PUNCT
ajcp-747	87	19	j.	j.	PROPN
ajcp-747	87	20	n.	n.	PROPN
ajcp-747	87	21	(	(	PUNCT
ajcp-747	87	22	2009	2009	NUM
ajcp-747	87	23	)	)	PUNCT
ajcp-747	87	24	.	.	PUNCT
ajcp-747	88	1	hyperglycemic	hyperglycemic	ADJ
ajcp-747	88	2	crises	crisis	NOUN
ajcp-747	88	3	in	in	ADP
ajcp-747	88	4	adult	adult	NOUN
ajcp-747	88	5	patients	patient	NOUN
ajcp-747	88	6	with	with	ADP
ajcp-747	88	7	diabetes	diabetes	NOUN
ajcp-747	88	8	.	.	PUNCT
ajcp-747	89	1	diabetes	diabetes	NOUN
ajcp-747	89	2	care	care	NOUN
ajcp-747	89	3	,	,	PUNCT
ajcp-747	89	4	32(7	32(7	NOUN
ajcp-747	89	5	)	)	PUNCT
ajcp-747	89	6	,	,	PUNCT
ajcp-747	89	7	1335	1335	NUM
ajcp-747	89	8	-	-	SYM
ajcp-747	89	9	1343	1343	NUM
ajcp-747	89	10	.	.	PUNCT
ajcp-747	90	1	munro	munro	PROPN
ajcp-747	90	2	,	,	PUNCT
ajcp-747	90	3	j.	j.	PROPN
ajcp-747	90	4	,	,	PUNCT
ajcp-747	90	5	campbell	campbell	PROPN
ajcp-747	90	6	,	,	PUNCT
ajcp-747	90	7	i.	i.	PROPN
ajcp-747	90	8	,	,	PUNCT
ajcp-747	90	9	mccuish	mccuish	PROPN
ajcp-747	90	10	,	,	PUNCT
ajcp-747	90	11	a.	a.	PROPN
ajcp-747	90	12	,	,	PUNCT
ajcp-747	90	13	&	&	CCONJ
ajcp-747	90	14	duncan	duncan	PROPN
ajcp-747	90	15	,	,	PUNCT
ajcp-747	90	16	l.	l.	PROPN
ajcp-747	90	17	(	(	PUNCT
ajcp-747	90	18	1973	1973	NUM
ajcp-747	90	19	)	)	PUNCT
ajcp-747	90	20	.	.	PUNCT
ajcp-747	91	1	euglycaemic	euglycaemic	ADJ
ajcp-747	91	2	diabetic	diabetic	ADJ
ajcp-747	91	3	ketoacidosis	ketoacidosis	NOUN
ajcp-747	91	4	.	.	PUNCT
ajcp-747	92	1	br	br	PROPN
ajcp-747	92	2	med	med	PROPN
ajcp-747	92	3	.	.	PUNCT
ajcp-747	93	1	j.	j.	PROPN
ajcp-747	93	2	,	,	PUNCT
ajcp-747	93	3	2(5866	2(5866	PROPN
ajcp-747	93	4	)	)	PUNCT
ajcp-747	93	5	,	,	PUNCT
ajcp-747	93	6	578	578	NUM
ajcp-747	93	7	-	-	SYM
ajcp-747	93	8	580	580	NUM
ajcp-747	93	9	.	.	PUNCT
ajcp-747	94	1	nyenwe	nyenwe	PROPN
ajcp-747	94	2	,	,	PUNCT
ajcp-747	94	3	e.	e.	PROPN
ajcp-747	94	4	a.	a.	PROPN
ajcp-747	94	5	,	,	PUNCT
ajcp-747	94	6	&	&	CCONJ
ajcp-747	94	7	kitabchi	kitabchi	PROPN
ajcp-747	94	8	,	,	PUNCT
ajcp-747	94	9	a.	a.	PROPN
ajcp-747	94	10	e.	e.	PROPN
ajcp-747	94	11	(	(	PUNCT
ajcp-747	94	12	2016	2016	NUM
ajcp-747	94	13	)	)	PUNCT
ajcp-747	94	14	.	.	PUNCT
ajcp-747	95	1	the	the	DET
ajcp-747	95	2	evolution	evolution	NOUN
ajcp-747	95	3	of	of	ADP
ajcp-747	95	4	diabetic	diabetic	ADJ
ajcp-747	95	5	ketoacidosis	ketoacidosis	NOUN
ajcp-747	95	6	:	:	PUNCT
ajcp-747	95	7	an	an	DET
ajcp-747	95	8	update	update	NOUN
ajcp-747	95	9	of	of	ADP
ajcp-747	95	10	its	its	PRON
ajcp-747	95	11	etiology	etiology	NOUN
ajcp-747	95	12	,	,	PUNCT
ajcp-747	95	13	pathogenesis	pathogenesis	NOUN
ajcp-747	95	14	and	and	CCONJ
ajcp-747	95	15	management	management	NOUN
ajcp-747	95	16	.	.	PUNCT
ajcp-747	96	1	metabolism	metabolism	NOUN
ajcp-747	96	2	,	,	PUNCT
ajcp-747	96	3	65(4	65(4	PROPN
ajcp-747	96	4	)	)	PUNCT
ajcp-747	96	5	,	,	PUNCT
ajcp-747	96	6	507	507	NUM
ajcp-747	96	7	-	-	SYM
ajcp-747	96	8	521	521	NUM
ajcp-747	96	9	.	.	PUNCT
ajcp-747	97	1	peters	peters	PROPN
ajcp-747	97	2	,	,	PUNCT
ajcp-747	97	3	a.	a.	PROPN
ajcp-747	97	4	l.	l.	PROPN
ajcp-747	97	5	,	,	PUNCT
ajcp-747	97	6	buschur	buschur	PROPN
ajcp-747	97	7	,	,	PUNCT
ajcp-747	97	8	e.	e.	PROPN
ajcp-747	97	9	o.	o.	PROPN
ajcp-747	97	10	,	,	PUNCT
ajcp-747	97	11	buse	buse	NOUN
ajcp-747	97	12	,	,	PUNCT
ajcp-747	97	13	j.	j.	PROPN
ajcp-747	97	14	b.	b.	PROPN
ajcp-747	97	15	,	,	PUNCT
ajcp-747	97	16	cohan	cohan	PROPN
ajcp-747	97	17	,	,	PUNCT
ajcp-747	97	18	p.	p.	PROPN
ajcp-747	97	19	,	,	PUNCT
ajcp-747	97	20	diner	diner	NOUN
ajcp-747	97	21	,	,	PUNCT
ajcp-747	97	22	j.	j.	PROPN
ajcp-747	97	23	c.	c.	PROPN
ajcp-747	97	24	,	,	PUNCT
ajcp-747	97	25	&	&	CCONJ
ajcp-747	97	26	hirsch	hirsch	PROPN
ajcp-747	97	27	,	,	PUNCT
ajcp-747	97	28	i.	i.	PROPN
ajcp-747	97	29	b.	b.	PROPN
ajcp-747	97	30	(	(	PUNCT
ajcp-747	97	31	2015	2015	NUM
ajcp-747	97	32	)	)	PUNCT
ajcp-747	97	33	.	.	PUNCT
ajcp-747	98	1	euglycemic	euglycemic	ADJ
ajcp-747	98	2	diabetic	diabetic	ADJ
ajcp-747	98	3	ketoacidosis	ketoacidosis	NOUN
ajcp-747	98	4	:	:	PUNCT
ajcp-747	98	5	a	a	DET
ajcp-747	98	6	potential	potential	ADJ
ajcp-747	98	7	complication	complication	NOUN
ajcp-747	98	8	of	of	ADP
ajcp-747	98	9	treatment	treatment	NOUN
ajcp-747	98	10	with	with	ADP
ajcp-747	98	11	sodium	sodium	NOUN
ajcp-747	98	12	–	–	PUNCT
ajcp-747	98	13	glucose	glucose	NOUN
ajcp-747	98	14	cotransporter	cotransporter	NOUN
ajcp-747	98	15	2	2	NUM
ajcp-747	98	16	inhibition	inhibition	NOUN
ajcp-747	98	17	.	.	PUNCT
ajcp-747	99	1	diabetes	diabetes	NOUN
ajcp-747	99	2	care	care	NOUN
ajcp-747	99	3	,	,	PUNCT
ajcp-747	99	4	38(9	38(9	NOUN
ajcp-747	99	5	)	)	PUNCT
ajcp-747	99	6	,	,	PUNCT
ajcp-747	99	7	1687	1687	NUM
ajcp-747	99	8	-	-	SYM
ajcp-747	99	9	1693	1693	NUM
ajcp-747	99	10	.	.	PUNCT
ajcp-747	100	1	pfützner	pfützner	ADJ
ajcp-747	100	2	,	,	PUNCT
ajcp-747	100	3	a.	a.	NOUN
ajcp-747	100	4	,	,	PUNCT
ajcp-747	100	5	klonoff	klonoff	NOUN
ajcp-747	100	6	,	,	PUNCT
ajcp-747	100	7	d.	d.	PROPN
ajcp-747	100	8	,	,	PUNCT
ajcp-747	100	9	heinemann	heinemann	PROPN
ajcp-747	100	10	,	,	PUNCT
ajcp-747	100	11	l.	l.	PROPN
ajcp-747	100	12	,	,	PUNCT
ajcp-747	100	13	ejskjaer	ejskjaer	PROPN
ajcp-747	100	14	,	,	PUNCT
ajcp-747	100	15	n.	n.	NOUN
ajcp-747	100	16	,	,	PUNCT
ajcp-747	100	17	&	&	CCONJ
ajcp-747	100	18	pickup	pickup	PROPN
ajcp-747	100	19	,	,	PUNCT
ajcp-747	100	20	j.	j.	PROPN
ajcp-747	100	21	(	(	PUNCT
ajcp-747	100	22	2017	2017	NUM
ajcp-747	100	23	)	)	PUNCT
ajcp-747	100	24	.	.	PUNCT
ajcp-747	101	1	euglycemic	euglycemic	ADJ
ajcp-747	101	2	ketosis	ketosis	NOUN
ajcp-747	101	3	in	in	ADP
ajcp-747	101	4	patients	patient	NOUN
ajcp-747	101	5	with	with	ADP
ajcp-747	101	6	type	type	NOUN
ajcp-747	101	7	2	2	NUM
ajcp-747	101	8	diabetes	diabetes	NOUN
ajcp-747	101	9	on	on	ADP
ajcp-747	101	10	sglt2	sglt2	ADJ
ajcp-747	101	11	-	-	PUNCT
ajcp-747	101	12	inhibitor	inhibitor	NOUN
ajcp-747	101	13	therapy	therapy	NOUN
ajcp-747	101	14	—	—	PUNCT
ajcp-747	101	15	an	an	DET
ajcp-747	101	16	emerging	emerge	VERB
ajcp-747	101	17	problem	problem	NOUN
ajcp-747	101	18	and	and	CCONJ
ajcp-747	101	19	solutions	solution	NOUN
ajcp-747	101	20	offered	offer	VERB
ajcp-747	101	21	by	by	ADP
ajcp-747	101	22	diabetes	diabetes	NOUN
ajcp-747	101	23	technology	technology	NOUN
ajcp-747	101	24	.	.	PUNCT
ajcp-747	102	1	endocrine	endocrine	PROPN
ajcp-747	102	2	,	,	PUNCT
ajcp-747	102	3	56(1	56(1	NUM
ajcp-747	102	4	)	)	PUNCT
ajcp-747	102	5	,	,	PUNCT
ajcp-747	102	6	212	212	NUM
ajcp-747	102	7	-	-	SYM
ajcp-747	102	8	216	216	NUM
ajcp-747	102	9	.	.	PUNCT
ajcp-747	103	1	rosenstock	rosenstock	PROPN
ajcp-747	103	2	,	,	PUNCT
ajcp-747	103	3	j	j	PROPN
ajcp-747	103	4	,	,	PUNCT
ajcp-747	103	5	f.	f.	PROPN
ajcp-747	103	6	e.	e.	PROPN
ajcp-747	103	7	(	(	PUNCT
ajcp-747	103	8	2015	2015	NUM
ajcp-747	103	9	)	)	PUNCT
ajcp-747	103	10	.	.	PUNCT
ajcp-747	104	1	euglycemic	euglycemic	ADJ
ajcp-747	104	2	diabetic	diabetic	ADJ
ajcp-747	104	3	ketoacidosis	ketoacidosis	NOUN
ajcp-747	104	4	:	:	PUNCT
ajcp-747	104	5	a	a	DET
ajcp-747	104	6	predictable	predictable	ADJ
ajcp-747	104	7	,	,	PUNCT
ajcp-747	104	8	detectable	detectable	ADJ
ajcp-747	104	9	,	,	PUNCT
ajcp-747	104	10	and	and	CCONJ
ajcp-747	104	11	preventable	preventable	ADJ
ajcp-747	104	12	safety	safety	NOUN
ajcp-747	104	13	concern	concern	NOUN
ajcp-747	104	14	with	with	ADP
ajcp-747	104	15	sglt2	sglt2	ADJ
ajcp-747	104	16	inhibitors	inhibitor	NOUN
ajcp-747	104	17	.	.	PUNCT
ajcp-747	105	1	diabetes	diabetes	NOUN
ajcp-747	105	2	care	care	NOUN
ajcp-747	105	3	,	,	PUNCT
ajcp-747	105	4	38(9	38(9	NOUN
ajcp-747	105	5	)	)	PUNCT
ajcp-747	105	6	,	,	PUNCT
ajcp-747	105	7	1638	1638	NUM
ajcp-747	105	8	-	-	SYM
ajcp-747	105	9	1642	1642	NUM
ajcp-747	105	10	.	.	PUNCT
ajcp-747	106	1	https://doi.org/	https://doi.org/	PROPN
ajcp-747	106	2	doi	doi	NOUN
ajcp-747	106	3	:	:	PUNCT
ajcp-747	106	4	10.2337	10.2337	NUM
ajcp-747	106	5	/	/	SYM
ajcp-747	106	6	dc15	dc15	PROPN
ajcp-747	106	7	-	-	PUNCT
ajcp-747	106	8	1380	1380	NUM
ajcp-747	106	9	.	.	PUNCT
ajcp-747	107	1	sampani	sampani	PROPN
ajcp-747	107	2	,	,	PUNCT
ajcp-747	107	3	e.	e.	PROPN
ajcp-747	107	4	,	,	PUNCT
ajcp-747	107	5	sarafidis	sarafidis	PROPN
ajcp-747	107	6	,	,	PUNCT
ajcp-747	107	7	p.	p.	NOUN
ajcp-747	107	8	,	,	PUNCT
ajcp-747	107	9	&	&	CCONJ
ajcp-747	107	10	papagianni	papagianni	PROPN
ajcp-747	107	11	,	,	PUNCT
ajcp-747	107	12	a.	a.	NOUN
ajcp-747	107	13	(	(	PUNCT
ajcp-747	107	14	2020	2020	NUM
ajcp-747	107	15	)	)	PUNCT
ajcp-747	107	16	.	.	PUNCT
ajcp-747	108	1	euglycaemic	euglycaemic	ADJ
ajcp-747	108	2	diabetic	diabetic	ADJ
ajcp-747	108	3	ketoacidosis	ketoacidosis	NOUN
ajcp-747	108	4	as	as	ADP
ajcp-747	108	5	a	a	DET
ajcp-747	108	6	complication	complication	NOUN
ajcp-747	108	7	of	of	ADP
ajcp-747	108	8	sglt-2	sglt-2	NUM
ajcp-747	108	9	inhibitors	inhibitor	NOUN
ajcp-747	108	10	:	:	PUNCT
ajcp-747	108	11	epidemiology	epidemiology	NOUN
ajcp-747	108	12	,	,	PUNCT
ajcp-747	108	13	pathophysiology	pathophysiology	NOUN
ajcp-747	108	14	,	,	PUNCT
ajcp-747	108	15	and	and	CCONJ
ajcp-747	108	16	treatment	treatment	NOUN
ajcp-747	108	17	.	.	PUNCT
ajcp-747	109	1	expert	expert	ADJ
ajcp-747	109	2	opinion	opinion	NOUN
ajcp-747	109	3	on	on	ADP
ajcp-747	109	4	drug	drug	NOUN
ajcp-747	109	5	safety	safety	NOUN
ajcp-747	109	6	,	,	PUNCT
ajcp-747	109	7	19(6	19(6	NUM
ajcp-747	109	8	)	)	PUNCT
ajcp-747	109	9	,	,	PUNCT
ajcp-747	109	10	673	673	NUM
ajcp-747	109	11	-	-	SYM
ajcp-747	109	12	682	682	NUM
ajcp-747	109	13	.	.	PUNCT
ajcp-747	110	1	sarafidis	sarafidi	NOUN
ajcp-747	110	2	,	,	PUNCT
ajcp-747	110	3	p.	p.	NOUN
ajcp-747	110	4	,	,	PUNCT
ajcp-747	110	5	ferro	ferro	NOUN
ajcp-747	110	6	,	,	PUNCT
ajcp-747	110	7	c.	c.	PROPN
ajcp-747	110	8	j.	j.	PROPN
ajcp-747	110	9	,	,	PUNCT
ajcp-747	110	10	morales	morales	PROPN
ajcp-747	110	11	,	,	PUNCT
ajcp-747	110	12	e.	e.	PROPN
ajcp-747	110	13	,	,	PUNCT
ajcp-747	110	14	ortiz	ortiz	PROPN
ajcp-747	110	15	,	,	PUNCT
ajcp-747	110	16	a.	a.	PROPN
ajcp-747	110	17	,	,	PUNCT
ajcp-747	110	18	malyszko	malyszko	PROPN
ajcp-747	110	19	,	,	PUNCT
ajcp-747	110	20	j.	j.	PROPN
ajcp-747	110	21	,	,	PUNCT
ajcp-747	110	22	hojs	hojs	ADJ
ajcp-747	110	23	,	,	PUNCT
ajcp-747	110	24	r.	r.	PROPN
ajcp-747	110	25	,	,	PUNCT
ajcp-747	110	26	khazim	khazim	PROPN
ajcp-747	110	27	,	,	PUNCT
ajcp-747	110	28	k.	k.	PROPN
ajcp-747	110	29	,	,	PUNCT
ajcp-747	110	30	ekart	ekart	PROPN
ajcp-747	110	31	,	,	PUNCT
ajcp-747	110	32	r.	r.	PROPN
ajcp-747	110	33	,	,	PUNCT
ajcp-747	110	34	valdivielso	valdivielso	PROPN
ajcp-747	110	35	,	,	PUNCT
ajcp-747	110	36	j.	j.	PROPN
ajcp-747	110	37	,	,	PUNCT
ajcp-747	110	38	&	&	CCONJ
ajcp-747	110	39	fouque	fouque	PROPN
ajcp-747	110	40	,	,	PUNCT
ajcp-747	110	41	d.	d.	PROPN
ajcp-747	110	42	(	(	PUNCT
ajcp-747	110	43	2019	2019	NUM
ajcp-747	110	44	)	)	PUNCT
ajcp-747	110	45	.	.	PUNCT
ajcp-747	111	1	sglt-2	sglt-2	NUM
ajcp-747	111	2	inhibitors	inhibitor	NOUN
ajcp-747	111	3	and	and	CCONJ
ajcp-747	111	4	glp1	glp1	NOUN
ajcp-747	111	5	receptor	receptor	NOUN
ajcp-747	111	6	agonists	agonist	NOUN
ajcp-747	111	7	for	for	ADP
ajcp-747	111	8	nephroprotection	nephroprotection	NOUN
ajcp-747	111	9	and	and	CCONJ
ajcp-747	111	10	cardioprotection	cardioprotection	NOUN
ajcp-747	111	11	in	in	ADP
ajcp-747	111	12	patients	patient	NOUN
ajcp-747	111	13	with	with	ADP
ajcp-747	111	14	diabetes	diabetes	NOUN
ajcp-747	111	15	mellitus	mellitus	NOUN
ajcp-747	111	16	and	and	CCONJ
ajcp-747	111	17	chronic	chronic	ADJ
ajcp-747	111	18	kidney	kidney	NOUN
ajcp-747	111	19	disease	disease	NOUN
ajcp-747	111	20	.	.	PUNCT
ajcp-747	112	1	a	a	DET
ajcp-747	112	2	consensus	consensus	NOUN
ajcp-747	112	3	statement	statement	NOUN
ajcp-747	112	4	by	by	ADP
ajcp-747	112	5	the	the	DET
ajcp-747	112	6	eureca	eureca	NOUN
ajcp-747	112	7	-	-	PUNCT
ajcp-747	112	8	m	m	NOUN
ajcp-747	112	9	and	and	CCONJ
ajcp-747	112	10	the	the	DET
ajcp-747	112	11	diabesity	diabesity	NOUN
ajcp-747	112	12	working	work	VERB
ajcp-747	112	13	groups	group	NOUN
ajcp-747	112	14	of	of	ADP
ajcp-747	112	15	the	the	DET
ajcp-747	112	16	era	era	NOUN
ajcp-747	112	17	-	-	PUNCT
ajcp-747	112	18	edta	edta	NOUN
ajcp-747	112	19	.	.	PUNCT
ajcp-747	113	1	nephrology	nephrology	NOUN
ajcp-747	113	2	dialysis	dialysis	NOUN
ajcp-747	113	3	transplantation	transplantation	NOUN
ajcp-747	113	4	,	,	PUNCT
ajcp-747	113	5	34(2	34(2	NUM
ajcp-747	113	6	)	)	PUNCT
ajcp-747	113	7	,	,	PUNCT
ajcp-747	113	8	208	208	NUM
ajcp-747	113	9	-	-	SYM
ajcp-747	113	10	230	230	NUM
ajcp-747	113	11	.	.	PUNCT
ajcp-747	114	1	somagutta	somagutta	NOUN
ajcp-747	114	2	,	,	PUNCT
ajcp-747	114	3	m.	m.	NOUN
ajcp-747	114	4	r.	r.	PROPN
ajcp-747	114	5	,	,	PUNCT
ajcp-747	114	6	agadi	agadi	PROPN
ajcp-747	114	7	,	,	PUNCT
ajcp-747	114	8	k.	k.	PROPN
ajcp-747	114	9	,	,	PUNCT
ajcp-747	114	10	hange	hange	PROPN
ajcp-747	114	11	,	,	PUNCT
ajcp-747	114	12	n.	n.	NOUN
ajcp-747	114	13	,	,	PUNCT
ajcp-747	114	14	jain	jain	PROPN
ajcp-747	114	15	,	,	PUNCT
ajcp-747	114	16	m.	m.	PROPN
ajcp-747	114	17	s.	s.	PROPN
ajcp-747	114	18	,	,	PUNCT
ajcp-747	114	19	batti	batti	PROPN
ajcp-747	114	20	,	,	PUNCT
ajcp-747	114	21	e.	e.	PROPN
ajcp-747	114	22	,	,	PUNCT
ajcp-747	114	23	emuze	emuze	PROPN
ajcp-747	114	24	,	,	PUNCT
ajcp-747	114	25	b.	b.	PROPN
ajcp-747	114	26	o.	o.	PROPN
ajcp-747	114	27	,	,	PUNCT
ajcp-747	114	28	amos	amos	PROPN
ajcp-747	114	29	-	-	PUNCT
ajcp-747	114	30	arowoshegbe	arowoshegbe	PROPN
ajcp-747	114	31	,	,	PUNCT
ajcp-747	114	32	e.	e.	PROPN
ajcp-747	114	33	o.	o.	PROPN
ajcp-747	114	34	,	,	PUNCT
ajcp-747	114	35	popescu	popescu	PROPN
ajcp-747	114	36	,	,	PUNCT
ajcp-747	114	37	s.	s.	PROPN
ajcp-747	114	38	,	,	PUNCT
ajcp-747	114	39	hanan	hanan	PROPN
ajcp-747	114	40	,	,	PUNCT
ajcp-747	114	41	s.	s.	PROPN
ajcp-747	114	42	,	,	PUNCT
ajcp-747	114	43	&	&	CCONJ
ajcp-747	114	44	kumar	kumar	PROPN
ajcp-747	114	45	,	,	PUNCT
ajcp-747	114	46	v.	v.	PROPN
ajcp-747	114	47	r.	r.	PROPN
ajcp-747	114	48	(	(	PUNCT
ajcp-747	114	49	2021	2021	NUM
ajcp-747	114	50	)	)	PUNCT
ajcp-747	114	51	.	.	PUNCT
ajcp-747	115	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-747	115	2	pa	pa	PROPN
ajcp-747	115	3	ge	ge	PROPN
ajcp-747	115	4	4	4	NUM
ajcp-747	115	5	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-747	115	6	am	be	AUX
ajcp-747	115	7	.	.	PUNCT
ajcp-747	116	1	j.	j.	PROPN
ajcp-747	116	2	chem	chem	PROPN
ajcp-747	116	3	.	.	PUNCT
ajcp-747	117	1	pharm	pharm	PROPN
ajcp-747	117	2	.	.	PUNCT
ajcp-747	118	1	1(2	1(2	NUM
ajcp-747	118	2	)	)	PUNCT
ajcp-747	118	3	1	1	NUM
ajcp-747	118	4	-	-	SYM
ajcp-747	118	5	4	4	NUM
ajcp-747	118	6	,	,	PUNCT
ajcp-747	118	7	2022	2022	NUM
ajcp-747	118	8	euglycemic	euglycemic	ADJ
ajcp-747	118	9	diabetic	diabetic	ADJ
ajcp-747	118	10	ketoacidosis	ketoacidosis	NOUN
ajcp-747	118	11	and	and	CCONJ
ajcp-747	118	12	sodium	sodium	NOUN
ajcp-747	118	13	-	-	PUNCT
ajcp-747	118	14	glucose	glucose	NOUN
ajcp-747	118	15	cotransporter-2	cotransporter-2	NUM
ajcp-747	118	16	inhibitors	inhibitor	NOUN
ajcp-747	118	17	:	:	PUNCT
ajcp-747	118	18	a	a	DET
ajcp-747	118	19	focused	focus	VERB
ajcp-747	118	20	review	review	NOUN
ajcp-747	118	21	of	of	ADP
ajcp-747	118	22	pathophysiology	pathophysiology	NOUN
ajcp-747	118	23	,	,	PUNCT
ajcp-747	118	24	risk	risk	NOUN
ajcp-747	118	25	factors	factor	NOUN
ajcp-747	118	26	,	,	PUNCT
ajcp-747	118	27	and	and	CCONJ
ajcp-747	118	28	triggers	trigger	NOUN
ajcp-747	118	29	.	.	PUNCT
ajcp-747	119	1	cureus	cureus	NOUN
ajcp-747	119	2	,	,	PUNCT
ajcp-747	119	3	13(3	13(3	NUM
ajcp-747	119	4	)	)	PUNCT
ajcp-747	119	5	.	.	PUNCT
ajcp-747	120	1	taylor	taylor	PROPN
ajcp-747	120	2	,	,	PUNCT
ajcp-747	120	3	s.	s.	PROPN
ajcp-747	120	4	i.	i.	PROPN
ajcp-747	120	5	,	,	PUNCT
ajcp-747	120	6	blau	blau	PROPN
ajcp-747	120	7	,	,	PUNCT
ajcp-747	120	8	j.	j.	PROPN
ajcp-747	120	9	e.	e.	PROPN
ajcp-747	120	10	,	,	PUNCT
ajcp-747	120	11	&	&	CCONJ
ajcp-747	120	12	rother	rother	PROPN
ajcp-747	120	13	,	,	PUNCT
ajcp-747	120	14	k.	k.	PROPN
ajcp-747	120	15	i.	i.	PROPN
ajcp-747	120	16	(	(	PUNCT
ajcp-747	120	17	2015	2015	NUM
ajcp-747	120	18	)	)	PUNCT
ajcp-747	120	19	.	.	PUNCT
ajcp-747	121	1	sglt2	sglt2	PROPN
ajcp-747	121	2	inhibitors	inhibitor	NOUN
ajcp-747	121	3	may	may	AUX
ajcp-747	121	4	predispose	predispose	VERB
ajcp-747	121	5	to	to	ADP
ajcp-747	121	6	ketoacidosis	ketoacidosis	NOUN
ajcp-747	121	7	.	.	PUNCT
ajcp-747	122	1	the	the	DET
ajcp-747	122	2	journal	journal	NOUN
ajcp-747	122	3	of	of	ADP
ajcp-747	122	4	clinical	clinical	ADJ
ajcp-747	122	5	endocrinology	endocrinology	NOUN
ajcp-747	122	6	&	&	CCONJ
ajcp-747	122	7	metabolism	metabolism	NOUN
ajcp-747	122	8	,	,	PUNCT
ajcp-747	122	9	100(8	100(8	NUM
ajcp-747	122	10	)	)	PUNCT
ajcp-747	122	11	,	,	PUNCT
ajcp-747	122	12	28492852	28492852	NUM
ajcp-747	122	13	.	.	PUNCT
ajcp-747	123	1	wibawa	wibawa	PROPN
ajcp-747	123	2	,	,	PUNCT
ajcp-747	123	3	k.	k.	PROPN
ajcp-747	123	4	,	,	PUNCT
ajcp-747	123	5	kuhuwael	kuhuwael	PROPN
ajcp-747	123	6	,	,	PUNCT
ajcp-747	123	7	f.	f.	PROPN
ajcp-747	123	8	v.	v.	PROPN
ajcp-747	123	9	,	,	PUNCT
ajcp-747	123	10	putra	putra	PROPN
ajcp-747	123	11	,	,	PUNCT
ajcp-747	123	12	c.	c.	PROPN
ajcp-747	123	13	r.	r.	PROPN
ajcp-747	123	14	j.	j.	PROPN
ajcp-747	123	15	,	,	PUNCT
ajcp-747	123	16	widiastuti	widiastuti	PROPN
ajcp-747	123	17	,	,	PUNCT
ajcp-747	123	18	s.	s.	PROPN
ajcp-747	123	19	u.	u.	PROPN
ajcp-747	123	20	,	,	PUNCT
ajcp-747	123	21	&	&	CCONJ
ajcp-747	123	22	suciadi	suciadi	PROPN
ajcp-747	123	23	,	,	PUNCT
ajcp-747	123	24	l.	l.	PROPN
ajcp-747	123	25	p.	p.	PROPN
ajcp-747	123	26	(	(	PUNCT
ajcp-747	123	27	2021	2021	NUM
ajcp-747	123	28	)	)	PUNCT
ajcp-747	123	29	.	.	PUNCT
ajcp-747	124	1	euglycemic	euglycemic	ADJ
ajcp-747	124	2	diabetic	diabetic	ADJ
ajcp-747	124	3	ketoacidosis	ketoacidosis	NOUN
ajcp-747	124	4	associated	associate	VERB
ajcp-747	124	5	with	with	ADP
ajcp-747	124	6	empagliflozin	empagliflozin	PROPN
ajcp-747	124	7	in	in	ADP
ajcp-747	124	8	patients	patient	NOUN
ajcp-747	124	9	hospitalized	hospitalize	VERB
ajcp-747	124	10	with	with	ADP
ajcp-747	124	11	acute	acute	ADJ
ajcp-747	124	12	pulmonary	pulmonary	ADJ
ajcp-747	124	13	embolism	embolism	NOUN
ajcp-747	124	14	.	.	PUNCT
ajcp-747	125	1	clinical	clinical	ADJ
ajcp-747	125	2	diabetology	diabetology	NOUN
ajcp-747	125	3	,	,	PUNCT
ajcp-747	125	4	10(2	10(2	NUM
ajcp-747	125	5	)	)	PUNCT
ajcp-747	125	6	,	,	PUNCT
ajcp-747	125	7	204	204	NUM
ajcp-747	125	8	-	-	SYM
ajcp-747	125	9	208	208	NUM
ajcp-747	125	10	.	.	PUNCT
ajcp-747	126	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	NOUN